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ABSTRACT 
Homocysteine is a natural occurring aminothiol. It is an intermediate product in the 
metabolism of methionine. Methionine is an essential amino acid required for protein 
synthesis. Metabolic irregularities disrupt homocysteine levels in plasma. Elevated 
homocysteine levels are directly linked to folate and cobalamin (vitamin B12) 
deficiencies, and are an independent risk factor for cardiovascular diseases. High 
homocysteine levels have also been associated with Alzheimer’s, osteoporosis, renal 
failure, cancer, birth defects and pregnancy complications. The association of elevated 
homocysteine levels with cardiovascular disease and other diseases has generated great 
interest in the detection of homocysteine.  
An optical method for the detection of homocysteine has been developed using 
fluorescein mono- and dialdehydes. Selectivity for homocysteine was achieved based on 
the characteristic differences between 5- and 6-membered ring heterocyclic amines 
formed upon the reaction with fluorescein mono- and dialdehydes. 6-membered ring 
homocysteine-derived thiazinane-4-carboxylic acids were found to be more basic than 5-
membered cysteine-derived thiazolidine-4-carboxylic acids. Fluorescence enhancement 
in response to homocysteine was thus attained by tuning pH and excitation wavelengths. 
Furthermore, the design and synthesis of a more sensitive fluorophore, fluorescein tri 
aldehyde has been accomplished based on the aforementioned findings to enable the 
detection of homocysteine at physiological levels. Calculations of Mulliken charges 
revealed that the formation of thiazinanes results in modulation of the electron density on 
the fluorophore leading to higher fluorescence.  
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CHAPTER 1 INTRODUCTION 
The low molecular weight thiols homocysteine (Hcy), cysteine (Cys) and glutathione 
(GSH) play a crucial role in metabolism and homeostasis. They are vital cell components 
that serve as antioxidants to maintain the redox balance in the human body. Aberrant 
levels in their concentrations results in metabolic disturbances that are linked to several 
diseases [1]. 
1.1 Hcy, Cys and GSH: structural features and functions.                                       
 Hcy is a sulfur containing non-essential amino acid. It is a metabolic intermediate 
derived from the essential sulfur containing amino acid methionine (Met). Hcy shares 
structure resemblance with another low molecular weight thiol, Cys, with the exception 
that it contains one more methylene group in its side chain, as shown in Figure 1-1.  
Thiol-like properties of Hcy are common to GSH and Cys.  
     
                        
                                     Figure 1-1.  Structures of selected biological thiols 
 
Hcy is present in various forms in human plasma. Total Hcy is the sum of all 
different species of Hcy i.e. protein bound, oxidized and reduced or free forms and it is 
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referred as tHcy [2]. The major form is disuflude bound to proteins, mainly albumin.  
The protein bound form of Hcy constitutes 70-80 % of total Hcy. Other oxidized forms 
such as Hcy-Hcy (Hcy disulfide) accounts for 5-10%, Hcy-Cys disulfide accounts for 5-
10% of the tHcy, and reduced Hcy sulfhydril accounts for less than 1% in human plasma. 
In general, the levels of tHcy in a healthy humans is approximately 5-15 μM, and 
increases with ageing. The condition in which the level of Hcy in human plasma rises 
above 15 μM is called ‘hyperhomocysteinemia’. There are three stages of 
hyperhomocysteinemia; mild, in which the Hcy level is 15-30μM; moderate,  in which 
the level is 30-100μM and for the level above >100 μM of Hcy, it is termed as severe 
hyperhomocysteinemia [3]. 
Cys is the lowest molecular weight biological thiol. Among the three major 
biological thiols, cysteine is the most abundant extracellular thiol. It varies from 150-300 
μM [4, 5]. Cys is produced during Hcy metabolism. Therefore, Hcy and Cys levels are 
highly related to each other. Cys plays an essential role in protein synthesis, redox 
chemistry and peptide cross-linking, detoxification and other metabolic processes [6, 7]. 
GSH is a tripeptide wherein glycine and Cys are linked by normal peptide linkage 
and amine group of Cys is attached to the carbonyl group of glutamate side chain via 
gamma peptide linkage. Thus, GSH is indirectly linked to homocysteine metabolism. It is 
known for its antioxidant properties. It is also involved in gene expression, cell 
proliferation and apoptosis [8]. GSH concentrations are very high in cells. They range 
from 1 to 5 mM, whereas its concentration in plasma is 1 to 6 μM [5, 8].  
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1.2 Metabolism of Hcy 
The metabolism of Hcy is intricately linked to the metabolic pathway of methionine, one 
of the essential amino acids [9]. Hcy is thus a vital part of cellular homeostasis in human 
body. Methionine is essential for protein synthesis; it acts as a methyl donor for the 
synthesis of a wide range of vital methylated compounds such as DNA, RNA etc. [10]. 
Hcy is the key intermediate of the transsulfuration pathway to produce several other 
sulfur-bearing amino acids such as, cystathionine, Cys, taurine, GSH, etc. [11]. Hcy is the 
foremost source of sulfur for inorganic sulfate. It also is linked to polyamine 
biosynthesis. Furthermore, Hcy plays a crucial part in folate metabolism, as well as in the 
catabolism of choline and betaine [10]. 
Hcy metabolism is shown in Figure 1-2. Hcy levels depend on the proper 
functioning of the enzymes involved in its metabolism. These include enzymes involved 
in the remethylation reaction pathway to form methionine (Met), such as betaine 
methyltransferase (BMT), S-adenosylhomocysteine hydrolase (SAHH), methionine 
synthase (MS), methionine adenosyltransferase (MAT) and S-adenosylmethione (S-
AdoMet)-dependent methyl transferases e.g., glycine methyltransferase. Methionine 
synthase depends on methionine synthase reductase, vitamin B12 and 5-
methyltetrahydrofolate obtained from methylenetetrahydrofolate reductase (MTHFR). A 
second pathway in Hcy metabolism is transsulphuration to produce cystathione, Cys and 
inorganic sulphates. This latter pathway mainly involves the enzyme cystathionine β- 
synthase (CBS) [12]. 
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 In the remethylation step, Hcy is converted to Met by a complex 5-
methyltetrahydrofolate- dependent reaction [13]. 5-methyl tertrahydrofolate is produced 
by 5,10-methylenetetrahydrofolate in the presence of MTHFR. The remethylation 
reaction is catalyzed by MS. This enzyme gets reductively methylated by methionine 
synthase reductase. The synthesis of methionine synthase reductase requires cobalamine 
(vitamin B12) and S-AdoMet. Additionally, Hcy can be remethylated to Met in a process 
promoted by betaine via betaine methyl transferase (BMT). Remethylating enzyme BMT 
is only found in liver, kidney and brain. MS, however, it has a wide tissue distribution 
[14].   
Met is transformed to its active form S-AdoMet. This reaction is catalyzed by 
methionine adenosyl transferase (MAT) [13]. S-AdoMet acts as a methyl donor for the 
production of a large number methylated biomolecules such as methylated DNA, RNA, 
lipids and proteins [14]. To date, 39 S-AdoMet dependent methyl transferases have been 
discovered in mammals [1]. After donating a methyl group, S-AdoMet becomes S-
adenosylhomocysteine (S-AdoHcy). To complete the Hcy metabolism cycle, S-AdoHcy 
undergoes hydrolysis to produce Hcy and adenosine. The enzyme Ado-Hcy hydrolase 
catalyzes this hydrolysis [14]. S-AdoMet also undergoes decarboxylation to provide a 
propyl amine moiety for the synthesis of spermine and spermidine[13]. However, this 
reaction consumes less than 10% of the total S-AdoMet[15]. (Figure 1-3)  
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Figure 1-2.  Homocysteine-methionine  metabolism. 
Enzymes involved in in Hcy metabolism : MAT-methionine adenosyltransferase, X-MT-various S-AdoMet 
dependent methyltransferases, SAHH-S-adenosylhomocysteine hydrolase, MS-methionine 
synthase, BMT-betaine methyltransferase,  MTHFR methylenetetrahydrofolate reductase, CBS cystathioni
ne β-synthase, γCL, γ-cystathionase, SHM serine hydroxymethylase. This figure was adopted from [14] 
and redrawn with some modifications.  
 
In the alternate Hcy transsulfuration [11] pathway, the first step involves 
condensation of Hcy with serine to produce cystathionine. This condensation takes place 
in the presence of cystathionine β-synthase (CBS). Pyridoxal 5phosphate (vitamin B6) is 
a cofactor for CBS. In the second step, cystathionine converts to Cys and a by-product α- 
oxo butyrate. The enzyme - cystathionase catalyzes this step and, like CBS, requires 
pyridoxal 5phosphate [14]. Cys is essential for the synthesis of the antioxidant 
glutathione. By a variety of enzymatic reactions and oxidation, cysteine produces 
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inorganic sulfates [16].  
1.2.1 Summary of enzymes involved in the regulation of Met and Hcy 
(1).  ATP: L-Methionine S-Adenosyltransferase: This enzyme facilitates the formation of 
vitally important S-AdoMet by catalyzing the transfer of adenosyl moiety from ATP to 
Met [14]. This reaction takes place in the presence of Mg
2
 and K
 
[17]. Two of the forms 
of S-AdoMet are specific to liver i.e. a tetramer MAT(I), which is an α form and a dimer 
MAT(III), which is a β form. The gene MAT1A encodes both forms in the liver. This 
gene is capable of reacting with high Met immediately.  
(2). S-AdoMet-dependent methyltransferases (glycine N-methyltransferase GNMT): 
GNMT is one of the S-AdoMet-dependent methyltransferases that converts glycine to 
sarcosine by the transfer of a methyl group from S-AdoMet [14]. By donating a methyl 
group, S-AdoMet transforms to S-AdoHcy. S-AdoHcy is an inhibitor of the enzyme MS. 
Any disturbance in the ratio of S-AdoMet to S-AdoHcy affects the activity of MS [14]. 
(3). S-AdoHcy Hydrolase: This enzyme has a binding site for adenosine. Therefore, it 
facilitates S-AdoHcy hydrolysis to form Hcy and release adenosine [9]. 
(4). Methionine Synthase (5-Methyltetrahydrofolate: Homocysteine Methyltransferase ): 
This enzyme catalyzes the remethylation reaction to form Met [9]. MS assists the transfer 
of the methyl group from 5-methyl THF to Hcy to form Met. MS maintains the folate and 
Met cycle to endow enough Met for S-AdoMet-dependent transmethylation reactions 
[14]. This enzyme encompasses zinc and four domains to bind Hcy, S-AdoMet, 
cobalmine cofactor and methylene tetrahydrofolate [18]. 
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(5). Methionine Synthase Reductase (Methionine Synthase Cob(II)alamine Reductase): 
MS would be inactive if the cobalamine factor exists as cob(II)alamine [14]. To activate 
methionine synthase, cob(II)amine needs to be reduced to cob(I)alamine. Reduction 
requires conversion of S-AdoMet to S-AdoHcy. This overall process is expedited by the 
enzyme methionine synthase reductase [14]. A complete reaction mechanism is described 
in Figure1-4.  
  
Figure 1-3. Redox and methylation reaction mechanism of methionine synthase: 
methionine synthase (MS) reductase; and tetrahydrofolate (THF). This figure was adopted form [14] and 
redrawn with some modifications.  
 
(6). Betaine Homocysteine Methyltransferase (BMT): This enzyme also transforms Hcy 
to Met [14]. Betaine acts as a methyl donor in the process [13]. Betaine is the product of 
the catabolism of choline [13]. Betaine methyltransferase is mainly present in the liver 
and the kidney.  
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(7) 5,10 Methylenetetrahydrofolate Reductase (MTHFR): 5-methyltetrahydrofolate is 
synthesized from 5,10-methylenetetrahydrofolate with the help of MTHFR [9]. This 
NADPH-associated reduction process provides a methyl group for vital compounds such 
as DNA and RNA and controls the folate coenzyme entry in the remethylation pathway 
for Hcy metabolism [14].  
(8). Cystathionine –synthase (CBS): L-cystathionine, the precursor for the synthesis of 
Cys, is produced by the condensation of Hcy and serine [14]. This condensation is 
expedited by CBS which is a cytosolic pyridoxal 5' phosphate-requiring enzyme. This 
enzyme mainly occurs in human liver [14].   
1.3. Hcy and human health  
As described in the previous section, Hcy is the key intermediate in the Met and Cys 
synthesis. Any alternation in these two metabolic pathways i.e. remethylation and 
transsulfuration, may result in abnormal levels of Hcy. Elevated levels of Hcy are directly 
linked to a number of pathologies mainly cardiovascular diseases [19], Alzheimer’s [20], 
birth defects and pregnancy complications [21], osteoporosis[22], renal failure [23], 
cancer [24], inflammatory bowel disease [25], and cancer[24]. Normal Hcy levels can be 
disturbed by several factors such as a deficiency of enzymes involved in Hcy metabolism 
(for example cystathionine –synthase (CBS), MTHFR,  MS)[11], inadequacy of vitamin 
B6, B12 and/or folic acid [2], overburdening of dietary methionine and buildup of 
excessive reactive oxygen species (ROS) [3]. Other factors that affect Hcy homeostasis 
include heavy smoking, caffeine and alcohol consumption, specific drugs, renal 
dysfunction, life style, age and gender [26]. A deficiency of folate or defects in MTHFR 
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alter the formation of 5-methyltetrahydrofolate that results in lower concentrations of S-
AdoMet and overloading of Hcy for the transsulfuration pathway. Furthermore, 
insufficient levels of S-AdoMet also suppress the transsulfuaration pathway, and this 
overall process leads to the accumulation of excessive Hcy in the cells, followed by its 
transfer to the blood stream producing hyperhomocysteinemia [11]. It is also caused by 
defects in CBS, responsible for transsulfuration pathway, which forces Hcy to proceed 
via remethylation to produce excess S-AdoMet. This eventually leads to feedback 
inhibition of MTHFR impeding the remethylation process. This causes severe 
hyperhomocysteinemia wherein the entire Hcy metabolism is impaired [11]. A number of 
diseases associated with hyperhomocysteinemia are listed below.  
Cardiovascular diseases (CVD) 
Hcy has been established as an independent risk factor for cardiovascular diseases. A 
number of published studies indicate the direct link between CVD and elevated levels of 
Hcy [27-30]. According to an early study by WHO, CVD mortality rate and Hcy levels 
are closely related to each other.  
 In 1969, McCully published a report about two patients, 2 months and 8 years 
old, with homocystinuria. Homocystinuria is a form of very severe 
hyperhomocysteinimia wherein homocysteine overload leads to its excretion in urine. 
McCully’s young patients suffered from premature atherosclerosis due to a deficiency of 
CBS [31]. Since that time, a wide variety of studies have been published suggesting 
modestly higher level of Hcy are a risk factor for atherosclerosis [32]. An association 
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between plasma Hcy and mortality rate was published by Refsum et al. Their study 
revealed that the mortality rate was 24.7 % in CVDs patient with plasma Hcy >15μM 
[19]. Recently, Tentolouris et al. indicated that acute Met-induced hperhomocysteinemia 
affects myocardial performance and impairs aortic distensibility [27].  
The occurrence of hyperhomocysteinemia is assessed to be 5% in the general 
population and 13% to 47% among patients suffering from symptomatic atherosclerotic 
vascular disease [26]. A meta-analysis of cross-sectional epidemiologic studies revealed 
that a 60% higher occurrence of ischemic heart disease was noticed with increase in each 
5 μM concentration level of plasma Hcy [33]. Cross-sectional studies and prospective 
studies both confirm that the incidence of myocardial infarction was increased by 3.4 fold 
when the concentration of Hcy was more than 16 μM. The mortality rates of CVD 
patients was 4.5 fold higher at a Hcy concentration higher than 20 μM [34].  
A multivariate analysis conducted by Boutouyrie et al. indicated that out of Hcy, 
Cys and GSH, only Hcy was directly linked with carotid artery remodeling, suggesting 
that Hcy is the only plasma thiols that acts as an independent risk factor for CVD [35]. 
Meta-analysis studies presented a correlation of plasma Hcy concentration with 
ischaemic heart disease, deep vein thrombosis, pulmonary embolism and stroke [32]. 
Both genetic and prospective studies revealed lowering Hcy concentration by 3μM 
reduced the risk of ischaemic heart diseases by 16%, deep vein thrombosis by 25 % and 
stroke by 24 % [32].  Also, a prospective study conducted on women with a risk of 
myocardial infarction found that fasting Hcy levels are positively related with myocardial 
infarction risk in women [36]. 
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Alzheimer’s disease (AD) 
Hyperhomocysteinemia has been also considered to be an independent risk factor for 
cognitive impairment, dementia and Alzheimer’s disease (AD) [20]. According to the 
National Health and Nutrition Examination Survey (NHANES III), hyperhomocysteinem
ia is directly linked to weak memory in elderly people. A survey was conducted on 
participants over 60 years of age. Participants with greater Hcy levels and lower folate 
levels received a lower score on short delayed recall tests [37].  
AD has been associated with an increased level of Hcy, along with a deficiency of 
vitamin B6, B12 and folic acid [38]. Elevated levels of Hcy and S-AdoHcy deter the 
remethylation processes of Met and S-AdoMet. This affects the methylation of various 
vital components such as DNA and protein, eventually damaging the vascular structure, 
neurotoxicity and causing apoptosis.  
 According to Lehman et al. unusual high levels of Hcy were found in patients 
suffering from AD as compared to a control group [39]. Ueland et al. published a study 
that presented considerably higher levels of Hcy along with a deficiency of folate and 
vitamin B12 in the AD patients. It also revealed that slight increases in Hcy levels have a 
strong effect on the risk of AD, and are 4.5 times greater in patients with Hcy 
levels ≥14μM compared to patients with ≤ 11μM [40].  Another case study conducted at 
the interval of 8 years on 1092 elderly patient stated that risk of AD was increased by 
40% with 5 μM increases in Hcy concentrations, whereas risk was doubled at Hcy 
concentrations ≥14μM [20]. 
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Neural tube defects (NTD) 
It is well known that the intake of folic acid during pregnancy can reduce the risk of 
neural tube birth defects. Levels of folate and vitamin B12 were found to be lower in the 
women carrying fetuses with NTD than the women with normal fetuses [41]. However, 
despite folate and vitamin B12 supplements, the risk of NTD remains elevated indicating 
that other metabolic factors are also responsible for this defect [42]. A case study 
reported by Scott et al. showed abnormal levels of Hcy present in the women with NTD 
fetuses. According to the authors, the abnormal levels were related to the defects in the 
enzyme methionine synthase [43]. This enzyme is necessary for methylation reaction 
such as DNA and myelin a basic protein, which may be a possible mechanism for NTD. 
Another factor responsible for NTD is the C677T and A1298C mutations in the 
(MTHFR) gene [44]. This can be regulated by folate supplement. However MTHFR 
polymorphism is a moderate risk factor for NDT in comparison to the methionine 
synthase.  
Osteoporosis  
In a 2005 review Herrmann et al. described a direct link between osteoporosis and Hcy 
levels. They explained that Hcy is not merely a risk indicator, it is also involved in bone 
metabolism [22]. A study conducted by Mudd et al. shows that ‘bone mineral density’ 
(BMD) was found to be lower in patients suffering from homocystinuria. Moreover, a 
risk of osteoporosis was found to be 50% by the age of 16 [45]. Studies conducted on 
large populations revealed that increases in Hcy levels elevate the risk of fragile bone 
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fractures [46, 47] Abnormal skeletal growth, skeletal deformities, an elongated 
appendicular skeleton and flattening of the vertebral bodies have been observed in 
homcystinuric patients [48-50]. According to a double-blind placebo-controlled 
intervention trial conducted by Sato et al. “Hcy lowering therapy treatment (5 mg of 
folate and 1500 g of vitamin B12)  was found to be effective in reducing the hip fracture 
rate in hemiplegic stroke patients [51]. The role of Hcy in osteoporosis is not clearly 
understood. It is believed that Hcy can affect bone metabolism in different ways; for 
instance, it can inhibit osteoblast formation and accelerate the osteoclast formation 
thereby affecting bone resorption. It can also lead to decreased bone blood flow. It  
inhibits collagen cross-linking, thereby reducing bone extracellular matrix (ECM) quality 
[22].  
In addition to the aforementioned disorders, Hcy has been linked to inflammatory 
bowel disease [25], diabetes [52] and cancer [24].  
 1.3.1 Hcy: A biomarker or a risk factor! 
Several clinical studies have successfully demonstrated a strong link between Hcy with 
CVD [19]. However, it has been a subject of debate from decades, whether Hcy is merely 
a biomarker or in fact a risk factor [53]. A proper mechanism for the role of Hcy in CVD 
has not been clearly understood. The efficiency of folic acid supplementation in stroke 
prevention was examined by a meta-analysis study [54]. The results indicated that folic 
acid supplementation may effectively reduce the risk of stroke for the patient [54]. A 
randomize controlled trial was conducted by Hess et al. on 553 patients to study the 
effect of Hcy lowering therapy by a combined supplement of  folic acid, vitamin B6 and 
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B12. The results revealed that after percutaneous coronary intervention, the frequency of 
major adverse events was substantially reduced [55]. Improvement in the stroke mortality 
was also reported in a government study after folic acid fortification in United States and 
Canada [56].  
 Nevertheless, another meta-analysis of randomized and controlled trial conducted 
by Saver et al. showed that folic acid and vitamin B12 combined together provided a very 
mild benefit to prevent primary stroke in male patient [57]. Similarly, McQueen et al. 
investigated the efficacy of Hcy-lowering therapy on stroke risk, severity and disability. 
Their 5 year study on 5522 adults with CVD demonstrated that a combined supplement 
of folate and vitamin B decreased the frequency of overall stroke but stroke severity and 
disability remained unaffected [58]. On the other hand, supplementation of vitamin B12 
along with folate as Hcy-lowering therapy for secondary prevention in patients that 
suffered from acute mycardinal infarction was published by Rasmussen et al. Their 
investigation revealed Hcy-lowering therapy had no impact on the risk of recurring CVD 
after myocardial infarction, in fact vitamin B12 had an adverse effect [59]. Similar cases 
were reported by Ebbing et al. where secondary prevention by folic acid and vitamin B 
supplementation in patients with coronary artery disease or aortic valve stenosis was 
found to be ineffective on CVD and total mortality [60]. Possible reasons for the failure 
of Hcy lowering therapy were explained by Blom et al. These include (1) the duration of 
these trials and interventions were not long enough to decide whether Hcy lowering 
therapy is helpful to prevent the risk of CVD. Most of these trials were conducted for less 
than 5 years. Since atherosclerotic plaque develops 30-40 years from initial growth to 
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clinical trials, Hcy lowering therapy may require a much longer period of trial than a 
relatively few years of study[61]. Reason two is that the majority of interventions 
understudied patients with greater levels of homocysteinimea (> 20μM), as mostly 
patients with just slightly higher levels of Hcy were included in the trials. Reason 3 is that 
the adverse effects of folate and vitamin B supplements were not taken into consideration 
in aggravating CVD. Fourth, a better understanding of the role of Hcy in damaging the 
vascular system is needed so that a proper study and treatment can be designed, apart 
from folate and Vitamin B supplementation. A fifth reason given is that Hcy lowering 
therapy was found to be ineffective because patients already had advanced CVD with a 
vascular system so impaired that folate and vitamin B supplementation was insufficient 
or too late to control the disease [61].  
 Regardless of whether Hcy is a biomarker or risk factor, a strong correlation 
between Hcy and CVD as well as other diseases generates a great demand to determine 
Hcy levels. Therefore, in this study, a method to detect Hcy has been developed.  
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The main objectives of this project are: 
1. Development of an optical method and design of a sensor for selective detection 
of Hcy. 
2. To detect Hcy at its physiological levels in addition to the elevated levels. 
3. To achieve a selective response of Hcy in presence of other related potentially 
interfering analytes, especially Cys, as well as in biological media.   
This thesis has been divided into five chapters. After an introduction in the first chapter, 
an overview of the current state of the art of techniques for Hcy detection is described in 
the second chapter. The third chapter explains the development of a novel optical method 
for the selective detection of Hcy using aldehyde bearing flurophores as sensors. In the 
fourth chapter, the mechanism behind the selectivity for Hcy is described. The fifth 
chapter includes the design and synthesis of a novel aldehyde bearing flurophore to 
achieve a sensitive and selective fluorescent signal in response to Hcy at biologically-
relevant concentrations.  
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CHAPTER 2 AN OVERVIEW – TECHNIQUES INVOLVED IN HCY 
DETECTION  
2.1 Introduction  
As describes in chapter one, elevated levels of Hcy are linked to a number of diseases, 
especially cardiovascular diseases. The association of Hcy levels with such life 
threatening diseases has generated a great interest in the scientific world to develop 
different methodologies for detection of this biomarker[62]. For example, high 
performance liquid chromatography (HPLC) [63-65], liquid chromatography/mass 
spectroscopy (LCMS) [66, 67], electrochemical [68-70], enzymatic [71, 72], and  
immunoassay [73] [72] and optical methods [74-79] have been employed to detect Hcy.  
2.2 Existing methods for the detection of Hcy 
In current diagnostic laboratories, techniques such as  HPLC [80], LCMS [81], enzymatic 
procedures [82-84], and immunoassays [85-87] are more prevalent for detection of Hcy. 
Their popularity is due to the sensitive and precise measurements of Hcy. However, these 
techniques also suffer from some disadvantages. For example, HPLC and UHPLC 
involve an additional derivatization step with a suitable reagent, and also require 
thorough sample preparation and labor intensive work with expensive instruments [2, 62, 
88-90]. LC/MS involved complicated sample preparation methods and expensive 
instruments [67, 91].  
The first immunoassay method was developed by Shipchandler and Moore in 
1995 [92]. tHcy is reduced to free Hcy by a suitable reducing agent. Next, Hcy is 
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enzymatically transformed to S-adenosyl-Hcy (SAH) by the action of S-adenosyl-Hcy 
hydrolase (SAHH). Anti SAH antibodies are used for the immunoassay of SAH via 
different techniques such as fluorescence polarization immunoassay (FPIA), 
chemiluminescence immunoassay (ICL), enzyme-linked immunoassay (EIA), the 
immune precipitation assay (IP) [93], For instance, Zappacosta et al. used anti-S-AdoHcy 
antibodies bound to polystyrene particles to bind SAH [73]. SAH had to compete for 
anti-SAH antibodies with thyroglobulin (TG) conjugated S-adenosyl-cysteine (SAC). The 
presence of SAH caused a weaker aggregation of polystyrene particles. In absence of 
SAH, TG-conjugated SAC induces a complete aggregation of polystyrene particles. The 
signal is measured by the scattered light which is inversely associated to SAH content 
[73]. However, the accuracy and adequate specificity of immunoassay techniques have 
been questioned in the past [94-96]. These methods suffer from the interferences such as 
effects of anticoagulants, icterus, hemolysis, lipemia, and sample storage [94, 95, 97]. 
Apart from that, analyte dependent interferences are produced by the interaction of 
sample component with one or more antibodies such as human anti-animal antibodies, 
auto-analyte, heterophilic antibodies, rheumatoid factor and other proteins [94, 95]. These 
interferences may lead to false results.  
In enzymatic procedures, cystathionine - β-synthase (CBS) was used to synthesize 
cystathionine from Hcy and serine [71]. With the help of γ-cystathionase lyase, 
cystathionine was converted to Cys, ammonina and pyruvate. Using lactate 
degydrogenase (LDA), the reduction of pyruvate was carried out along with the oxidation 
of NADH to NAD. The oxidation of NADH is measured by the spectroscopic methods 
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[71]. Immunoassays and enzymatic procedures also require fragile and relatively 
expensive biological material such as antibodies and other biomolecules. Therefore, their 
proper washing, handling and storage is necessary [2, 83]. Regardless of these 
complications, enzymatic procedures are the more commonly used methods on the 
clinical level compared to immunoassays, HPLC and LCMS.  The requirements of small 
amounts of reagents, less complicated procedures, sensitivity and high output make 
enzymatic procedure a method of interest for Hcy detection for regular clinical 
applications [71, 73, 83]. However, a comparative study of all these techniques for tHcy 
determination shows imprecision and variations in the results [98].  
2.3 Methods based on electrochemistry and nano materials  
Other techniques for Hcy detection have been reported in the literature that includes, the 
use of nano particles [99, 100] and electrochemical techniques[69, 88, 100, 101] etc.  
Recently, a silica nanoparticle based sensor was reported by Wu et al. [102]. They 
developed a mesoporus silica nanoparticle (MSN) based nanostructure as fluorescence 
sensor for detection of Hcy. They prepared a fluorescence sensor by embedding the 
anthracene nitroolefin inside the MSNs.  In the absence of biothiols, the electron deficient 
nitroolefin moiety quenches the fluorescence of electron rich anthrancene scaffold via 
intramolecular charge transfer (ICT). Later, Michael addition of thiols to the nitoolefin 
moiety prevents ICT, resulting in fluorescence enhancement.  Thus the probe acts as a 
fluorescence sensor for biological thiols.  Selectivity for Hcy was achieved with the help 
of covalently bound polyethylene glycol (PEG 5000) chains on the surface of the MSNs. 
Based on the polarity and the size of the molecules, these chains serve as a barrier for the 
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diffusion of different biological thiols inside the mesoporus nanoparticle. According to 
them, relative lower content of polar groups and smaller size make Hcy best candidate 
among all biological thiols, to pass through the barrier fastest and give a fluorescence 
turn on signal by Michael addition reaction. However size and the polarity of Cys is 
similar to that of Hcy but no explanation was given why Cys was not able to pass the 
barrier.  The sensor responded well towards Hcy, however equimolar concentrations of 
other thiols such as Cys and GSH were used in the detection method. Therefore, Cys is 
expected to cause interference at physiological levels, making the sensor ineffective for 
specific responses to Hcy in plasma. 
                                                                
      Scheme 2-1. Michael addition of Hcy on the nitroloefin moiety of 2.1 to prevent ITC that results in the 
fluorescence of 2.2. 
 
Yan et al. designed polyethyleneimine capped Ag-nanoclusters for Hcy detection 
by resonance light scattering technique (RSL) [99]. Hcy served as a bridge between the 
Ag core and polyethyleneimine (PEI) chains. This linking was due to the affinity of SH 
group of Hcy for the Ag core and the ionic interaction of the carboxylate group of Hcy 
with hyperbranched PEI chains. This resulted in the formation of a Ag-nanocluster 
assembly. These nanoclusters interacted with one another to produce oscillation coupling, 
enhancing the RSL signal.  This assembly showed selectivity for Hcy over Cys and 
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glutathione. However the instability of the Ag-particles makes it difficult to run the Hcy 
assay in practice [103].  
Several electrochemical detection techniques for Hcy detection have also been 
reported in the literature [69, 88, 100, 101].  For example, Campton et al. achieved 
responses for Hcy by an electrocatalytic reaction and 1,4 Michael addition of Hcy with 
catechol using a modified carbon nanotube glassy carbon electrode (CNT–GCE) [68, 69]. 
Though the electrochemical detection of Hcy was carried out in the presence of Cys, 
GSH and ascorbic acid using carbon electrode, the response for Hcy was not achieved at 
a physiological level in the presence of other thiols and amino acids as well as in any 
biological media [68]. 
Kerman et al. developed another electrochemical method wherein electrodepositi
on of gold on carbon nanotubes was employed for the enhanced electrochemical 
detection of Hcy. They recorded the response of Hcy at very high concentrations (mM 
level), and no information was given about other interfering thiols, amino acids and 
biological media [100].   
 On the other hand, an amperometric Hcy biosensor array (HBA) was developed 
by Ching et al. for the determination of Hcy. They fabricated amperometric HBA with a 
D-amino acid oxidase (AAOx) immobilized on a screen printed carbon electrode[104]. 
Silver-silver chloride (Ag-AgCl) was used as a reference electrode. Detection sensitivity 
was found to be the best with 8 working electrodes. Though this method was sensitive, it 
involved several steps and was found to be time consuming. Moreover, they do not report 
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the response of Cys and GHS, capable of undergoing the same oxidation mechanism as 
Hcy, eventually causing interference with the response of Hcy. (Scheme 2-2)  
 
Scheme 2-2. The enzymatic oxidation of homocysteine by D-amino acid oxidase  to produce H2O2 
 
2.4 Optical methods. 
Optical methods have received a great deal of attention for the detection of biological 
thiols [74-79]. The popularity of these methods is due to sensitivity, relative ease, and 
low cost; however, to date there have been relatively few optical methods, especially 
fluorescence methods, reported that can reliably distinguish Hcy over Cys, GSH and 
other amino acids [105-110].  
2.4.1 Optical detection based on the redox chemistry of Hcy 
Our group has published a photochemical method for the detection of homocysteine in 
whole plasma using viologens as redox based indicators [106, 107]. This mechanism, as 
shown in Scheme 2-3, relies on the reduction of viologens by the α-amino carbon 
centered radical of Hcy generated by intramolecular hydrogen atom transfer (HAT) of its 
thiyl radical [106, 107]. Addition of Hcy to a solution of viologen resulted in change in 
the absorbance spectra the viologen.  
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Scheme 2-3. Mechanism for the detection of Hcy involving by generation of thiyl radical, hydrogen atom 
transfer and reduction of BV
2+
  
 
Lately, Wang et al. also published a redox based fluorometric detection of 
homocysteine using a dansyl derivative as fluorescence probe [108] (Figure 2-1). The 
selectivity for Hcy was proposed due to the oxidation of dansyl derivative probe DN-2 by 
Hcy. Selectivity of the probe for Hcy over Cys was due to the formation of a favorable 
five membered intermediate derived from Hcy, as opposed to the strained four membered 
ring derived from Cys. They claimed the selectivity of Hcy over Cys and GSH, 
nonetheless the response of Hcy in presence Cys and GSH towards the probe, had a 
relatively very high fluorescence enhancement than the Hcy itself (almost two folds). 
Under physiological conditions, where levels of Cys are 15-20 times higher than Hcy, it 
would be confusing to decide whether the high response is from Hcy or Cys. 
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Figure 2-1. Structure of desyl derivative probe DN-2 
2.4.2 Methods for detection of Cys and Hcy based on Schiff base formation and 
subsequent cyclization to form a heterocycle.  
It is well know that, Cys and Hcy form thiazolidine and thiazinane heterocycles 
upon reaction with aldehyde moiety (for more details refer chapter 4). Based on this 
concept, some research groups have reported the detection of Hcy over Cys using 
aldehyde bearing fluorophores [105, 109, 110]. Huang et al. reported a phosphorescence 
sensor for Hcy detection based on an iridium (III) complex.  Figure 2-2). Photoinduced 
electron transfer (PET) from Cys-derived thiazolidine was believed to be responsible for 
specificity of iridium (III) complex towards Hcy over Cys. Enhancement of the 
photoluminescence upon addition of Hcy and quenching of the optical response with 
respect to Cys was obtained. This complex produced a very good signal for Hcy, 
nevertheless a response was achieved at a very high concentration (400 μM), far more 
than the physiological levels, and the use of excess of DMSO (90%) as a reaction 
medium makes it inapplicable in the biological sample.[109] 
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 Figure 2-2. Structure of phosphorescence sensor for Hcy based on iridium (III) complex,  Ir(pba)2(acac) 
(Hpba = 4-(2-pyridyl)-benzaldehyde; acac = acetylacetone) 
 
Yoon et al. reported  aldehyde bearing pyrene probes  (P-Hcy-1 and P-Hcy-2)  for 
the selective detection of Hcy [105] (Figure 2-3).  Addition of Hcy to a solution of pyrene 
aldehdyes resulted in fluorescence enhancement. They stated that the distinct 
fluorescence response of the probes towards Hcy and Cys was due to intramolecular 
charge transfer (ICT) and photoinduced electron transfer (PET). However, the response 
of Hcy at physiological levels in the presence of other interfering thiols was not reported. 
 
        
                                        Figure 2-3. Structures of P-Hcy-1 and P-Hcy-2. 
 
Recently, an aldehyde bearing bodipy based turn on NIR fluorescent probe 
containing a partially exposed aldehyde group at the meso position for the detection of 
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Hcy over Cys was published [110] (Figure 2-4). At the equimolar concentration of Hcy 
and Cys, after four hours, a 30 fold increase in the fluorescence was obtained for Hcy and 
a 9 folds increase in the fluorescence for Cys was observed. Under physiological 
conditions where Cys levels are 15-20 times higher than Hcy; hence, Cys will interfere 
with the selectivity for Hcy. This makes the sensor unsuitable for Hcy detection in the 
biological samples.  
 
                  Figure 2-4.  Structure of aldehyde bearing bodipy based sensor for Hcy detection 
 
Keeping the above information in mind, it is safe to say that it has been very 
challenging to design a molecule and develop a method which can deliver a distinctive 
response to Hcy in the presence of other biological thiols and amino acids at 
physiologically-relevant levels. 
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CHAPTER 3 SELECTIVE DETECTION OF HCY USING FLUORESCEINE 
ALDEHYDES  
3.1 Background  
It has been known for almost 90 years that Cys reacts with aldehydes and forms 
thiazolidines [111]. Aldehyde-functionalized probes have received a great deal of 
attention for the optical detection of aminothiols and amino acids [76-78, 105, 112-114] 
First aldehyde-bearing fluorophore for the detection of Cys and Hcy was developed by 
our group in 2004 [76]. These reactions are based on the well-known cyclization of the 
aldehyde group with aminothiols to form thiazinane/thiazolidine heterocycles, as shown 
in the Figure 3-1. The formation of these heterocycles affords a change in the electronic 
properties of the chromophore and gives a different optical response than the molecule 
itself.      
 
               Figure 3-1. General reaction scheme for reaction of carbonyl with Cys and Hcy  
 
Interestingly, this class of probes has responded to their respective analytes via 
either fluorescence quenching or fluorescence enhancement on a case by case basis. For 
instance, Glass et al. reported the detection of amino acids using aldehyde bearing 
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coumarin probes, wherein the reaction of the aldehyde with amino acids to form imines 
produced an enhancement of fluorescence [112]. Concurrently, Strongin and co-workers.  
presented the detection of biological thiols with aldehyde bearing fluorophores [76, 77] 
based upon the well-known reaction of aldehydes with N-terminal cysteine residues to 
form heterocycilic thiazolidines [115] and N-terminal homocysteine residues to form 
heterocyclic thiazinanes. They reported the fluorescence quenching of fluorescein 
aldehyde probes due to the formation of thiazolidines/thiazinanes heterocycles, upon 
reaction of Cys and Hcy [76]. Afterwards, several groups have implemented this concept 
of aldehyde bearing probes for the detection of Cys and Hcy [75]. For instance,  Kim 
et al. observed the fluorescence quenching of an aldehyde bearing amino coumarin based 
fluorophore in response to Cys/Hcy [113]. Hoang et al, reported an aldehyde bearing 
hydroxy coumarin [114] in which addition of Cys/Hcy resulted in enhancement of the 
fluorescence.    
 Another point of interest is that these aldehyde-based probes [76-78, 105, 112-
114, 116] have generally responded to the entire classes of analytes including amino 
acids[112] or biological thiols [113, 114] without specificity for individual analytes 
within each class. It is therefore of great interest and utility to develop a better 
understanding of the mechanisms behind different signal transduction in these related 
aldehyde-based probes. Such knowledge will lead to improved probes with increased 
sensitivity for the selected aminothiols of interest, specifically for Hcy over Cys.  
 Besides understanding the mechanism of signal transduction for respective 
analytes, it is equally important to focus on the difference in the spectroscopic responses 
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of the probe itself and the probe-analyte complex with respect to excitation wavelength 
(λex). In general, fluorescence responses of an analyte-indicator complexes are observed 
at an excitation wavelength that corresponds to the absorption maximum of the dye or 
indicator. However, the chosen excitation wavelength may not give the optimal response, 
since it corresponds to the maximum absorption of the dye in the absence of analyte 
[112]. In 2010, Strongin et al. had reported the optimum excitation wavelength for α,,β – 
unsaturated aldehyde-based sensor for the detection of biological thiols, which was 
different than the maximum absorption of sensor[78].  
Usually, selective detection is obtained due to the specific and distinctive 
interactions of analytes with sensors or receptors. However, different analytes or 
biomolecules present in biological media may interact with the indicator through similar 
supramolecular or covalent interactions. Therefore, the presence of these indicator-bound 
species may interfere with the selective detection of the desired analyte. To overcome this 
problem, Strongin et al. studied a simple approach for the selective detection of a target 
biomolecule [117]. This new approach is based on the concept that the structural 
differences among various complexes which were formed by the interaction of various 
analytes with the same sensor may produce distinctive absorption and emission 
responses. This potentially allows a multianalyte detection via a single optical indicator. 
Based on this concept, a tunable detection of specific saccharides was achieved with the 
help of the single optical indicator by the judicious selection of excitation and emission 
wavelengths[117]. For instance, selective detection of fructose and ribose derivatives was 
attained at different excitation and emission wavelengths as a function of time. A 
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rhodamine boronic acid was used as an indicator in that study.  
3.2 Mechanism of signal transaction in aldehyde bearing fluorophore probes upon 
reaction with aminothiols  
It is important to note the differences in the reaction of aldehyde-bearing probes with 
aminothiols compared to amino acids. Amino acids react to form Schiff bases [112] 
whereas, aminothiols such as Cys and Hcy react to form heterocyclic thiazolidines and 
thiazinanes respectively [76]. These differences result in unique optical responses 
towards aminothiols. The mechanism of signal transduction in fluorescein aldehyde 
probes upon their reaction with aminothiols was investigated in this work.  
 
Figure 3-2. Mechanism of signal transduction in generic aldehyde-bearing aminothiol probes.  
(a) PET-based fluorescence quenching following reaction of Cys/Hcy with the aldehyde group. (b) PET 
inhibition through hydrogen bonding between the amine-containing heterocycle and adjacent groups. (c) 
PET inhibition through protonation of the amine-containing heterocycle. 
 
There are several phenomena that impact the fluorescence response of aldehyde-
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bearing probes. Figure 3-2 depicts the reaction of Cys/Hcy with the aldehyde group of a 
generic aldehyde-bearing probe. The mechanistic understanding described herein, has led 
to control over signal transduction in such a way that the probe can be tuned to respond to 
Cys/Hcy through either quenching or enhancement. Importantly, the response can be 
controlled in such a manner that Hcy is detected selectively over Cys.  
It is well established that the free electrons of the amino group in the heterocycle 
can quench the fluorescence of the probe (Figure 3-2a) through photo induced electron 
transfer (PET) [113]. PET-induced responses have been modulated through tuning the 
functionality of the fluorescent probes [118],[114]. For example, hydrogen bonding in 
aqueous media between the amine-containing heterocycles and adjacent groups  (Figure 
3-2b) has been reported to inhibit PET leading to fluorescence enhancement upon 
reaction with both Cys and Hcy with a coumarin aldehyde [114]. Conversely, PET 
inhibition leading to selective fluorescence enhancement for Hcy/Cys can be achieved via 
a mechanism involving protonation of the amino group of the heterocycle. (Figure 3-2c) 
In this work, the above mentioned concepts were implemented based on the 
structural differences between the complexes of fluorescein dialdehyde (FDA) or 
/fluorescein monoaldehyde (FMA) with Cys and Hcy. Via different signal transduction 
mechanisms, a specific response for Hcy was achieved by varying the excitation and 
emission wavelengths as a function of time at specific pH values.  
3.3 Previous work- response of fluorescein aldehydes to Cys and Hcy 
Previously, in 2004, Strongin et al. investigated the reaction of 3.1(FMA), and 3.3 (FDA) 
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with Cys and Hcy at pH 9.5 [76, 77]. As described below in Scheme 3-1 , this is a very 
simple method for the detection of Cys or Hcy and doesn’t involve any complicated 
biochemical techniques or preparative separation [76, 77]. This protocol was developed 
on the same aforementioned concept i.e. the reaction of aldehyde with N- terminal Cys 
residue to form thiazolidines [115, 119]. 
 
 
Scheme 3-1. Reaction of FMA (3.1) and FDA (3.3) with Cys and Hcy to generate thiazolidines/ thiazinanes 
heterocycles respectively. 
 
In Scheme 3-1, as shown above, the addition of Cys and Hcy to a solution of 3.3 results 
in a change in solution color from yellow to orange. Optical studies have shown that the 
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addition of Cys to the solution of 3.3 produces a red shift in the absorption spectrum from 
480 nm to 495 nm which is shown in the Figure 3-3. Further, addition of Cys and Hcy to 
a solution of 3.3 has also been shown to result in a monitorable fluorescence quenching 
(excited at 460 nm) due to the formation of thiazolidines/thiazinanes as shown in Figure 
3-4 and Figure 3-5. Moreover, NMR spectra proved the formation of thiazolidines/ 
thiazinanes in this reaction [76]. “Figure 3-3, Figure 3-4 and Figure 3-5 were adapted 
with permission from [76] Copyright (2004) American Chemical Society." 
 
Figure 3-3. Change in the absorbance spectra of 3.3 upon addition of Cys in buffer, pH 9.5 at room 
temperature.  
Each spectrum was acquired after 5 min. As the concentration of Cys increases, a red shift from 480 nm to 
495 nm was observed. 
 
 
 
           
         
Figure 3-4. Quenching of the fluorescence emission of 3.3 upon addition of Cys, excited at 460 nm, pH 9.5 
at room temperature 
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Figure 3-5. Quenching of the fluorescence emission of 3.3 upon addition of Hcy , excited at 460 nm , pH 
9.5 at room temperature  
 
In these optical studies, under basic conditions (at pH 9.5) both Cys and Hcy 
displayed the same behavior towards 3.1 and 3.3 i.e. quenching of the fluorescence 
emission of fluorescein aldehydes. This was attributed to the photoinduced electron 
transfer (PET) of the lone pairs present on the nitrogen atom of heterocycles derived from 
Cys and Hcy.  
3.4 Present work – results and discussion  
In the current study, the objective was to optimize the system to develop a simple, 
convenient and inexpensive fluorescence method to serve as a sensitive analytical tool for 
the detection of Hcy. It was hypothesized that at sufficiently low pH, the amine of the 
heterocycles, which formed upon reaction with the probe, would be protonated, thereby 
inhibiting PET and leading to florescence enhancement. Moreover, we anticipated that 
the protonated amino groups in the thiazinane and thiazolidine would have different pKa 
values due to hybridization differences as a function of ring sizes. Hence, it was decided 
to study of response Hcy and Cys towards 3.1 and 3.3 at different pH values.  
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The behavior of the reaction products was found to vary at different pH, as shown 
in Figure 3-6, Figure 3-7 and Figure 3-8. At higher pH (9.5), Hcy and Cys both exhibited 
expected quenching of the fluorescence of 3.1 as both retain their amine lone pairs. At 
lower pH (5.5 and 6.0), Hcy enhanced the fluorescence of the fluorophore. However Cys 
displayed fluorescence quenching (Figure 3-8) at pH 6.0 (at pH = 5.5 there was no signal 
change). These results suggest that at pH = 6 the amine of the Hcy thiazinane was 
protonated (PET quenching off) and that of the cysteine thiazolidine was neutral (lone 
pairs retained and PET quenching on).  
In the case of a 5-memebered Cys-derived thiazolidine ring, the C-N-C bond 
angle is smaller than that in a 6-membered Hcy-derived thiazinane ring. This results in 
greater % S-character of the N-H bond in the thiazolidines, rendering them less basic than 
the thiazinanes[120-122]  
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Figure 3-6. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 9.5 
(a) fluorescence spectral changes of 3.1 with Hcy and Cys after 30 min. (b) Time dependent fluorescence 
spectral changes of 3.1 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte in 
carbonate buffer (100 mM, pH 9.5) DMSO 99:1 at 20 ºC, λex = 480 nm and λem = 515nm.  
 
 
Figure 3-7. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 5.5.  
(a)fluorescence spectral changes of 3.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence 
spectral changes of 3.31 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte 
in phosphate buffer (100 mM, pH 5.5) DMSO 99:1 at 20 ºC, λex = 480 nm and λem = 515nm.  
 
 
 
(a) (b) 
(b) (a) 
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Figure 3-8. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 6.0. 
(a) Fluorescence spectral changes of 3.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence 
spectral changes of 3.1 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte in 
phosphate buffer (100 mM, pH 6.0) DMSO 99:1 at 20 ºC, λex = 480 nm and λem = 515nm.  
 
The hypothesis and results showed that lowering the pH of the reaction medium 
results in the enhancement of the fluorescence of 3.1 in the presence of Hcy. After 
studying the responses to thiols as a function of pH, a study was conducted to explore the 
response of 3.1 towards Hcy and Cys at a different excitation wavelengths. It was again 
hypothesize that the fluorescence response would be maximum when excited at 
wavelength which is near the absorption maxima of the reaction product, instead of the 
absorption maxima of the probe itself. Based on this concept, maximum response for the 
detection of amino acids and Cys as well as tunable detection of saccharides[117] have 
been reported in the literature [78, 112, 117]. Absorbance spectra of 3.1, show that the 
addition of Hcy or Cys to a solution of 3.1, produces a red shift from 480 nm to 495 as a 
result of the formation of thiazinane/thiazolidine heterocycles ( 
 
 
(b) (a) 
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Figure 3-9) [76]. 
To prove this second hypothesis, the optical response of Cys and Hcy towards 3.1 
was monitored at higher excitation wavelengths, i.e. λex at 495 nm, near the absorption 
maxima of the heterocyclic reaction product. On exciting at 495 nm, enhancement in the 
fluorescence of 3.1 in response to Hcy was found to be 2 to 3 fold higher than the 
excitation at lower wavelength (at 480 nm, lambda max of the probe itself) as shown in 
Figure 3-10. Another interesting observation was that, on adjusting the pH from 5.5 to 
6.0, the signal is modulated such that Hcy enhances the fluorescence of 1 while there is 
minimal change upon reaction with Cys, as shown in Figure 3-11.  These observations 
led to a new method to achieve a maximum response of Hcy over Cys via adjusting the 
pH of the reaction medium and the excitation wavelength. In the present case, the best 
parameters are pH 6.0 and excitation wavelength, λex of 495nm.  
 
 
 
 
Figure 3-9. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 9.5.  
(a) Time dependent absorption spectral changes of 3.1 with Hcy over 30 min. (b) Time dependent 
absorption spectral changes of 3.1 with Cys over 30 min. Solutions are composed of 4 µM of 3.1 with 1 
mM of analyte in carbonate buffer (100 mM, pH 9.5) DMSO 99:1 at 20 ºC 
  
(a) (b) 
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Figure 3-10. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 5.5.  
(a) Fluorescence spectral changes of 3.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence 
spectral changes of 3.1 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte in 
phosphate buffer (100 mM, pH 5.5) DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 515nm. 
 
  
Figure 3-11. Optical sensing behavior of 3.1 towards Hcy and Cys at pH 6.0.  
(a) Fluorescence spectral changes of 3.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence 
spectral changes of 3.1 with Hcy and Cys. Solutions are composed of 4 µM of 3.1 with 1 mM of analyte in 
phosphate buffer (100 mM, pH 6.0) DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 515nm. 
 
The response of 3.1 towards GSH and various amino acids at pH 6.0 was also 
investigated. As shown in the Figure 3-12, it was found that only Hcy promotes 
fluorescence enhancement. 
(a) (b) 
(b) (a) 
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Figure 3-12. Optical sensing behavior of 3.1 towards Cys and Hcy as compared to other biologically 
relevant species.  
Fluorescence response of 3.1 upon addition of different analytes (Cys, Hcy, GSH,Asn, Ala, Gln, Thr, Asp, 
Arg, His, Glu, 1 mM). All Solutions are composed of 4 µM of 3.1 with 1 mM analyte in phosphate buffer 
(100 mM, pH 6.0):DMSO 99:1 at 20 ºC,  λex = 495nm λem = 515 nm 
 
1
HNMR study of 3.1 in the presence of Hcy and Cys under these conditions also confirms 
the formation of thiazinane and thiazolidine, upon reaction of Cys and Hcy with 3.1. 
Figure 3-13 shows disappearance of aldehyde resonance at 10.39 ppm and appearance of 
methine resonance at 6.81 ppm substantiate formation of these heterocycles. Whereas, 
1
H NMR experiment of 3.1 with glycine shows the formation of a Schiff base (an imine ), 
in the Figure 3-14, the Schiff base resonance at 9.11 ppm  along with CHO resonance at 
10.38 ppm shows the Schiff base formation was in equilibrium with the 3.1.  
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Figure 3-13. H
1
 NMR of 3.1, 3.1 in the presence of Hcy (3 equiv) and 3.1 in presence of Cys (3 equiv) at 
pH 6.0.  
   
 
42 
  
 
Figure 3-14. H
1
 NMR of 3.1 and 3.1 in the presence of Gly (3 equiv)  at pH 6.  
 
Although highly selective for Hcy over Cys, 3.1 was not sensitive enough to produce an 
appreciable response of Hcy at the lower levels. Therefore, it was decided to study the 
response of Hcy and Cys towards 3.3, i.e. fluorescein dialdehdye.  
The absorption spectra of 3.3 in the presence of Hcy and Cys are analogous to 
those using 3.1, including a red shift in the absorption maxima upon addition of Hcy and 
Cys from 480nm to 495 nm (Figure 3-15). Further, on exciting at a higher wavelength 
(λex= 495 nm), 3.3 produces a >5 fold enhancement in the fluorescence upon addition of 
Hcy (Figure 3-16). The signals using 3.3 were approximately twice as intense as from 
3.1. The response of 3.3 towards Hcy was easily observed in as little as 15 min and 
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plateaus near 45 min.  
 
  
Figure 3-15. Optical sensing behavior of 3.3 towards Hcy and Cys at pH 6.0.  
(a) Time dependent absorption spectral changes of 3.3 with Hcy over 2h. (b) Time dependent absorption 
spectral changes of 3.3 with Cys over 2h. Solutions are composed of 4 µM of 3.3 with 1 mM of analyte in 
Phosphate buffer (100 mM, pH 9.5) DMSO 99:1 at 20 ºC 
 
  
Figure 3-16. Optical sensing behavior of 3.3 towards Hcy and Cys at pH 6.0.  
(a) Fluorescence spectral changes of 3.3 with Hcy and Cys after 2h. (b) Time dependent fluorescence 
spectral changes of 3.3 with Hcy and Cys. Solutions are composed of 4 µM of 3.3 with 1 mM of analyte in 
phosphate buffer (100 mM, pH 6.0) DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 515nm. 
 
Having identified the optimal conditions for the discrimination of Hcy over Cys, the 
response of the more sensitive dialdehyde 3.3 towards normal healthy concentrations of 
aminothiols in pH 6.0 buffer was investigated. As shown in the Figure 3-17, No response 
(a) (b) 
(a) (b) 
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was observed toward 250 M Cys, while 15 M Hcy resulted in a ~10% increase in the 
fluorescence. The fluorescence response of 3.3 towards Hcy increased linearly with the 
increase in the Hcy concentration, and the limit of detection was found to be as low as 2.5 
M as shown in the Figure 3-18.  
 
Figure 3-17. Optical sensing behavior of 3.3 towards Cys and Hcy at their biological concentrations at pH 
6.0. 
Fluorescence spectra of 3.3 with Cys and Hcy after two hours. Solutions are composed of 30 µM of 3.3 
with 250 µM of Cys and 15 µM of Hcy in phosphate buffer (100 mM, pH 6.0):DMSO 99:1 at 20 
oC,  λex = 
494 nm. 
 
 
Figure 3-18. Spectral response of 3.3 towards increasing levels of Hcy in phosphate buffer (100 mM, pH 
6.0).  
Solutions are composed of 4 µM of 3.3 with 0-80 µM of Hcy in phosphate buffer (100 mM, pH 
6.0):DMSO 99:1at 20 
0C, λex = 494 nm and  λem = 515 nm. 
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The response of 3.3 in deproteinized plasma at elevated levels of Hcy was also 
investigated. To measure a known amount of Hcy deproteinized plasma was spiked with 
Hcy (100μM). Under this condition, 3.3 functioned well in the presence of spiked Hcy. 
The response of physiological levels of Cys (i.e. 250 μM) towards 3.3 was insignificant 
as shown in the Figure 3-19. 
 
Figure 3-19. Optical sensing behavior of 3.3 towards Cys and Hcy in deproteinized bovine plasma at pH 
6.0.  
Solutions are composed of 25 µM of 3.3 with 250 µM of Cys and 100 µM of Hcy in phosphate buffer (100 
mM, pH 6.0):DMSO 99:1 at 20 oC after 2 hr, λex = 495 nm. 
 
3.5 Conclusion  
In conclusion, the optimum conditions to attain the specific detection of Hcy via a 
characteristic fluorescence increase with 3.1 and 3.3 were identified. Under basic 
conditions, addition of Hcy and Cys to a solution of fluorescein aldehyde (3.1 or 3.3), 
resulted in fluorescence quenching due to the PET from the lone pair of electron, present 
on the nitrogen atom of heterocycles derived from Hcy and Cys. Whereas under acidic 
conditions, protonation of amine of Hcy/Cys derived heterocycles inhibits PET and 
produces fluorescence enhancement. pH 6.0 was found to be the optimal pH for the 
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detection of Hcy, at this pH the response to Hcy of 3.1 and 3.3 led to fluorescence 
enhancement, whereas the response to Cys was minimal.  
 Apart from the pH dependence, the detection of Hcy was also found to be 
wavelength dependent. The magnitude of the response was at the maximum when excited 
in the region near the absorption maxima of the analyte-probe complex (λex= 495nm) 
rather than the absorption maxima of probe itself ( λex= 480nm). Fluorescein dialdehyde 
(3.3) was found to be more sensitive than fluorescein mono aldehyde (3.1). The reaction 
of 3.3 with Hcy resulted in more than a fivefold enhancement in fluorescence. 3.3 was 
also found to function in deproteinized plasma, detecting relatively high levels of Hcy 
(100 M). 
3.6 Experimental section 
3.6.1 Materials  
All chemicals were purchased from Sigma Aldrich and used as received. Ultra-pure water 
(18.2 MΩ·cm at 25 °C) obtained from a Milli-Q direct water purification system was 
used to prepare all aqueous solutions. All spectroscopic measurements were carried out in 
DMSO:buffer (1:99) solutions. 3.1 and 3.3 were synthesized from the procedure reported 
in the literature based on the Reimer Tiemann reaction for formylation [77]. 
3.6.2 Methods  
1
H-NMR spectra were recorded on an ARX-400 Advance Bruker spectrometer 
performing at 400.13 MHz (
1
H). D2O:H2O (1:9) solvent system was used as NMR 
solvent. All chemical shifts (δ) were reported in ppm using DSS (sodium 2,2-dimetyl-2-
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silapentane-5-sulfonate) as an internal standard (=0.000) for 1H-NMR studies.  
3.6.3 Spectrophotometric measurement 
UV-visible spectra were recorded on a Cary 50 UV-Vis spectrophotometer (Agilent 
Technologies). Fluorescence spectra were obtained on a Cary Eclipse fluorescence 
spectrophotometer (Agilent Technologies) with slit widths set at 5 nm for both excitation 
and emission, respectively. Fluorescence spectra were corrected for the wavelength 
dependent response of the R928 photomultiplier tube with the help of a manufacturer 
generated correction file. All spectrophotometric measurements were conducted at room 
temperature.  
3.6.4 Deproteinization of plasma  
Deproteinization of plasma was carried out by reconstituting the lyophilized bovine 
plasma with ultrapure water to 1/3 of the reconstitution volume.  Two equivalents of 
acetonitrile (2/3 of the reconstitution volume) were added. This solution was vortexed for 
10 min. after letting the solution stand for 10 minutes, it was centrifuged at 4000 RPM for 
30 minutes to pellet the proteins.  The decanted supernatant was aliquoted into sample 
vials and re-lyophilized.  The vials were then sealed and stored in a refrigerator (4 ºC). 
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CHAPTER 4 MECHANISTIC STUDIES  
4.1 Introduction  
Fluorescence enhancement due to PET Inhibition is a well-known phenomenon.  [123] 
PET based fluorescence sensors have been widely used to detect an individual or a class 
of analytes [109, 113, 114, 123-125]. This effect has been observed in the case of 
fluorescein aldehydes. As seen in previous chapter, under acidic conditions, amine of 
Hcy-Cys derived heterocycles is protonated causing inhibition of PET and fluorescence 
enhancement. However, at an intermediate pH, the response of Hcy was observed but 
Cys seems to give minimal or insignificant response.  
4.2. Result and discussion 
Here the objective was to understand the difference in the fluorescence response of Hcy-
derived thiazinane and Cys-derived thiazolidine which are formed upon reaction of Hcy 
and Cys with 3.1 and 3.3 respectively. The difference in the response of Hcy than Cys 
towards 3.1/3.3 was possibly due to the difference in the pKa value of protonated amine 
of Hcy-derived thiazinane and the Cys-derived thiazolidine. Since, the C-N-C bond angle 
for 5-memebered Cys-derived thiazolidine ring is smaller than the 6-membered Hcy-
derived thiazinane ring, it generates a greater S-character of the N-H bond in the 
thiazolidines, making them less basic than the thiazinanes [120-122]. To prove this 
hypothesis, it was necessary to understand the difference in the basicity of amine of 
Hcy/Cys derived heterocycles. Previously, the basicity of the amine of thiazolidine-4-
caroboxylc acids has been studied [126-129] but the basicity of the amine of the Hcy-
derived thiazinane-4-carboxylic acids had not been reported. Therefore, a series of 5-
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 and 6-membered 2-substituted thiazolidine/thiazinaneS-4-carboxylic acids were 
synthesized as model compounds of 3.1 and 3.3.  
4.2.1 Synthesis of Cys- and Hcy-derived analogs 4.1, 4.3, 4.5, 4.2, 4.4 and 4.6 
To understand the difference in the basicity of 5- and 6-membered heterocyclic amines, 
the Cys- and Hcy-derived analogs 4.1, 4.3, 4.5, 4.2, 4.4 and 4.6 were synthesized. 4.1, 4.3 
and 4.5 were prepared by the reaction of Cys with salicylaldehyde, benzaldehyde and 
formaldehyde respectively in aqueous medium at room temperature. Several attempts 
were made for the synthesis of Hcy derived heterocycles analogs 4.2, 4.4 and 4.6. 
Reaction of Hcy was carried out with salicylaldehyde, benzaldehyde and formaldehyde 
respectively in aqueous and/or ethanol reaction medium by changing the number of 
equivalents, water/EtOH ratio and time over a period of few hours to 3 days. 4.2 and 4.4 
were obtained as colorless crystals from the reaction medium. However 4.6 remained 
soluble in the aqueous medium therefore ethanol was added to the reaction mixture and 
after 24 hours shiny colorless crystals of 4.6 were obtained.  
4.2.1 Estimated pKa values of  Cys- and Hcy-derived analogs 4.1, 4.3, 4.5, 4.2, 4.4 
and 4.6 
To confirm the hypothesis that the pH dependent Hcy enhancement was related to 
the difference in the basicity of 5- and 6-membered heterocyclic amines, the estimated  
pKa values of the protonated amine of the Cys- and Hcy-derived analogs were measured. 
The values are reported in the Table 4.1. estimated pKa values were calculated from the 
pH titration curves which are shown in Figure 4-1, Figure 4-2 and Figure 4-3. Cys-
derived 4.1, 4.3 and 4.5 are known [130, 131] and their previously published pKa values 
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are in general agreement with those in Table 4.1. As seen in Table 4.1, the protonated 
amine pKa of 6-membered thiazinanes is higher than that of 5-membered thiazolidines by 
at least one unit. Therefore, based on the pKa of these analogs, we expect the protonated 
amine pKa of Hcy-derived 3.2b to be approximately 1 unit greater (~6.7) than Cys-
derived 3.2a (~5.7). One unit difference in the pKa of amine of Hcy and Cys derived 
heterocyles will affect the ionization state of amine at a given pH. For instance, at pH 6.0 
major species for the amine of Hcy-derived thiazinane would exist mainly as the 
ammonium ion whereas the amine of the Cys-derived thiazolidine would be at a nearly 
equal concentration to the ammonium form.  
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Table 4.1. Estimated pKa values of the protonated amine moiety of 2-substituted thiazolidine/thiazinane-4-
carboxylic acids. 
Compound pKa exp, (pKa lit) Compound pKa exp 
           
                     
 
 
NA,
a
 (5. 67 [130]) 
     
           
6.67
b
 
 
                      
5.50,
a
 (5.31[130]) 
 
 
6.85
b
 
 
                      
6.44, (6.19) 
  
         
7.76 
a
4.1 and 4.3 were found to be relatively unstable showing signs of decomposition in aqueous 
solution during the course of the titration (Figure 4-1, Figure 4-2and Figure 4-4 ).  
b
4.2 and 4.4 showed no indication of decomposition (Figure 4-1, Figure 4-2 and Figure 4-4 ) 
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Figure 4-1. Average of triplicates of (a) pH titration curve and (b) derivatives of 4.1 and 4.2 
(a) 
(b) 
   
 
53 
  
 
Figure 4-2. Average of triplicates of (a) pH titration curve and (b) derivatives of 4.3 and 4.4 
 
 
(a) 
(b) 
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Figure 4-3. Average of triplicates of (a) pH titration curve and (b) derivatives of 4.5 and 4.6 
 
From the pH titration of thiazolidine-4-carboxylic acids, derivatives 4.1 and 4.3 were 
found to be unstable in the aqueous solutions; however, thiazinane-4-carboxylic acids 4.2 
and 4.4 appeared stable as shown in Figure 4-1 and Figure 4-2. Further, the stability of 
thiazolidines/thiazinane-4-carboxylic acids 4.1 and 4.2 were studied by 
1
HNMR 
experiments.  As shown in the , 
1
HNMR spectra of 4.1 and 4.2 were carried out in a 
mixture of D2O:H2O (9:1). In the 
1
HNMR of 4.1, the appearance of an aldehyde 
resonance at 9.88 ppm shows that 4.1 decomposes and goes back to starting material i.e 
(a) 
(b) 
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salicylaldehyde. On the other hand 
1
HNMR of 4.2 doesn’t show any aldehyde proton 
peak and the presence of a methine resonance at 5.7 ppm demonstrates the stability of 
this compound in aqueous medium, as shown in Figure 4.4. The instability of 
thiazolidine-4-carboxylic acids 4.1 and 4.3 in aqueous solutions has also been mentioned 
previously[130] (particularly in strongly basic and acidic medium [132]). 
 
Figure 4-4. 
1
H
 
NMR of salicylaldehyde-Cys derived thiazolidines 4.1 and salicylaldehyde-Hcy derived 
thiazinanes 4.2 in  D2O:H2O 
 
Table 1 and pH titration curves (Figure 4-1, Figure 4-2 and Figure 4-3) show the higher 
basicity of the amine of the thiazinane-4-carboxylic acids than the amine of thiazolidine-
4-carboxylic acids at least by one unit. This difference in basicity results in the selectivity 
Aldehyde peak  
reappears  
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for Hcy over Cys. For the purpose of investigating the mechanism responsible for this 
unique selectivity, first the simpler monoaldehyde 3.1 was studied. The response of 3.1 
towards Hcy and Cys over a range of pH values was investigated (Figure 4-5). From the 
pH dependent experiment, it is evident that, with a change in the pH values, the ratio of 
amine to ammonium ion in the Hcy/Cys derived heterocycles changes. That eventually 
affects the fluorescence response of 3.1 i.e. FMA (Figure 4-5).  As the pH is lowered, the 
percent of ammonium ion species increases, consequently the fluorescence enhancement 
increases linearly as a result of PET inhibition by the ammonium ion. Due to the higher 
pKa value of Hcy-derived thiazinane, there is a greater percent of ammonium ion species 
in the solution than the Cys-derived thiazolidines.  
At the appropriate pH, the ratio of ionization states of the amine moiety in 
thiazolidine 3.2a would be such that fluorescence quenching by the lone pair electrons is 
cancelled by PET inhibition from the ammonium species 3.2a' (Scheme 4-1). At this pH, 
the amine group in thiazinane 3.2b exists predominately as the more fluorescent 
ammonium 3.2b' (Scheme 4-1) because the pKa of 3.2b' is greater than that of 3.2a'. At 
pH 6.0, the reaction between 3.1 and Cys does not result in a change in fluorescence 
while reaction with Hcy results in fluorescence enhancement.  
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Scheme 4-1. Different ionization states of the the amine moieties in Cys- and Hcy-derived heterocycles at 
pH 6.0. 
 
Thus pH 6.0 is optimal for the detection of Hcy. Raising the pH increases the ratio of 
amine to ammonium which leads to quenching, while decreasing the pH leads to 
enhancement as clear from Figure 4-5.  
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(a) 
(b) 
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(d) 
(c) 
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Figure 4-5. Time dependent fluorescence spectral changes and enhancement factor (inset) of fluorescence 
of 3.1 with Cys and Hcy,(a) pH 5.5, (b) pH 6.0, (c) pH 6.5, (d) pH 7.0, (e) pH 7.4.  (f) comparison of 
fluorescence response of 3.1 towards Cys and Hcy at different pH.  
Solutions are composed of 4 µM of 3.1 with 1 mM analyte in phosphate buffer (100 mM, pH 6.0):DMSO 
99:1 at 20 ºC, λex = 495 nm and  λem = 515 nm. For Time dependent fluorescence spectral changes, λex =495 
and λem =515. Enhancement factor (EF) is the response of 3.1+ analyte divided by 1. When EF < 3.1 
quenching is observed, while when EF > 3.1 enhancement is observed. The vertical line in the enhancement 
factor plots is the experimentally determined optimal excitation wavelength of 495 nm. At pH 6.0  (b inset), 
excitation at 495 results in enhancement for Hcy but no enhancement for Cys in response to 3.1. 
 
(e) 
(f) 
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4.3 Conclusion  
In conclusion, a new approach for the selective detection of Hcy using fluorescein 
aldehyde-based probes has been developed. This method is based on intrinsic differences 
between the pKa of 5- and 6-membered thiazolidines and thiazinanes formed upon 
reaction with the aldehyde-bearing probes. At an optimum pH (6.0), amine of Hcy-
derived thiazinane is protonated to a greater extent (pKa~6.7) causing PET inhibition and 
fluorescence enhancement. Due to lower pKa value (~ 5.7) of the protonated amine of the 
Cys-derived thiazolidine, at pH 6.0, amine and ammonium ion species were seen in equal 
quantity and therefore, no optical response was observed. 
4.4 Experimental section 
4.4.1 Materials  
All chemicals were purchased from Sigma Aldrich and used as received. Ultrapure water 
obtained from a Milli-Q direct water purification system was used to prepare all aqueous 
solutions. All spectroscopic measurements were carried out in DMSO:buffer (1:99) 
solutions. All experiments were performed at room temperature.  
4.4.2 Methods  
1
H NMR and 
13
C NMR were recorded on an ARX-400 Advance Bruker spectrometer 
performing at 400.13 MHz (
1
H) and 100.61 MHz (
13
C). All chemical shifts (δ) were 
reported in ppm relative to DMSO-d6 (2.50 ppm, 
1
H; 39.52 ppm, 
13
C) unless otherwise 
indicated. For the study of stability of 4.1 and 4.3 in aqueous media, 
1
H NMR experiment 
was conducted in H2O : D2O mixture (9:1) using DSS (sodium 2, 2-dimetyl-2-
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silapentane-5-sulfonate) as an internal standard (=0.000). ESI-HRMS (high resolution 
mass spectrometry) were recorded at the PSU Bioanalytical Mass Spectrometry Facility 
on a ThermoElectron LTQ-Orbitrap high resolution mass spectrometer. IR spectrum was 
obtained by Fourier transform infrared (FT-IR) spectroscopy operated on a Thermo 
Scientific Nicolet iS10 spectrophotometer equipped with a single-bounce diamond ATR 
attachment.  
4.4.3 Spectrophotometric measurement 
Fluorescence spectra were obtained on a Cary Eclipse fluorescence spectrophotometer 
(Agilent Technologies) with slit widths set at 5 nm for both excitation and emission, 
respectively. Fluorescence spectra were corrected for the wavelength dependent response 
of the R928 photomultiplier tube with the help of a manufacturer generated correction 
file.  
4.4.4 pKa measurements 
pKa values of the amine of 2-substituted thiazolidines/thiazinaneS-4-carboxylic acids, 
4.1, 4.3, 4.5, 4.2, 4.4, and 4.6 were obtained by the titration of  their aqueous solutions 
with 0.01M NaOH by following the procedure reported in the literature [126]. In the case 
of 4.1 and 4.2, 0.1 M NaOH was used. The pH measurements were conducted using an 
Orion 410A pH meter, which was standardized with Scientific Products potassium 
hydrogen phthalate pH 4.00 buffer, BDH pH 7.00 and Scientific Products boric 
acid/potassium hydroxide pH 10.00 buffer. All pH titrations were conducted in triplicates 
and their average was reported.  
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4.4.5 Synthesis of compounds 4.1, 4.2, 4.3, 4.4, 4.5 and 4.6  
Scheme 4-1. Synthetic route of 4.1, 4.3 and 4.5 
 
Scheme 4-2. Synthetic route of 4.2, 4.4 and 4.6 
 
(2S,4R) and (2R,4R)-2-(2-hydroxy phenyl) thiazolidine-4-carboxylic acid (4.1) 
L-Cys (1.67 mmol) and salicylaldehyde (1.67 mmol) were added in 5 mL of DI H2O. 
Reaction mixture was stirred at RT for 2 h. The precipitates from the reaction mixture 
were filtered, washed with ice cold H2O and dried under vacuum to yield 4.1 as a 
mixture of distereoisomers, colourless solid (307 mg, 83%); max (film)/cm
1 
1738  (C= O)
; M.P.180-181
°
C; 
1H NMR (400 MHz, DMSO) δ 7.49 (m, 1H, Ar), 7. (m, 1H, Ar), 6.91 
(m, 2H, Ar), 5.84 (s, 1H, Ar-CH), 5.65 (s, 1H, Ar-CH), 4.26  (m, 1H, NH-
CH), 3.82 (m,1H, S˗CH2), 3.11 (m, 1H, S˗ CH2); 
13
C NMR (101 MHz, DMSO) 172.9˗ 
172.4 ( C=O), 155.1, 154.5, 129.00, 128.2, 126.00, 124.2, 119.00, 118.7, 115.6, 115.00,  
67.6, 66.6,  63.2 , 38.00, 37.00; Electrospray ionization (ESI) mass spectrometry (positive 
electron ionization) m/z :226.05602 ([M+H]
+
,100%), calculated for C10H11NO3S, m/z 
:225.04596. 
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(2S,4S) and (2R,4S)-2-(2-hydroxyphenyl)-1,3-thiazinane-4-carboxylic acid (4.2) 
L-Hcy (1.88 mmol) and salicylaldehyde (1.88 mmol) were added in a mixture of 6 mL of 
distilled water and 0.25 mL of ethanol. Reaction mixture was stirred at RT for 48 hrs. 
The resultant precipitates were filtered, washed with ice cold H2O and dried under 
vacuum to yield 4.2 as a mixture of distereoisomers, colourless solid.  
(322 mg, 82%);  max (film)/cm
1 
1738 (C=O); M.P.131-132
°
C; 
1
H-NMR (400 MHz, 
DMSO-d6); δ (ppm): 7.35 (m, 1H, Ar), 7.15 (m, 1H, Ar), 6.87 (m, 2H, Ar), 5.43 (s, 1H, 
Ar-CH), 3.59 (m, 1H, COCH), 3.22 (m, Hz, 1H, S-CH2), 2.89 (m, 1H, S-CH2), 2.08 (m, 
1H, CH-CH2), 1.50 (m,1H, CH-CH2); 
13
C-NMR (101 MHz, DMSO) 173.49(C=O), 
155.2, 154.1, 128.7, 127.8, 126.4, 125.8, 125.8, 118.9, 115.6, 59.3, 56.1, 54.8, 54.50, 28.7
7, 27.9, 26.4, 25.3 ; Electrospray ionization (ESI) mass spectrometry (positive electron io
nization) m/z : 240.07 182 ([M+H]
+
,100%), calculated for C11H13NO3S, m/z 239.06161. 
(2S,4R) and (2R,4R)-2-phenylthiazolidine-4-carboxylic acid (4.3) 
The synthesis of compound 4.3 has been reported in the literature [133]. Here an 
improved and simpler procedure has been used for its synthesis. Compound 4.3 was 
prepared according to the procedure described for 4.1. L-Cys (1.67 mmol) and (1.67 
mmol) benzaldehyde were added in 5 mL of DI H2O. Reaction mixture was stirred at RT 
for 2 h. The precipitates from the reaction mixture were filtered, washed with ice cold 
H2O and dried under vacuum. Compound 4.3 was obtained as a mixture of  distereoisome
rs, colourless solid (488 mg, 99%); max (film)/cm
1 
1668 (C=O); M.P.175-176 
°
C; 
1
HMNR resonance  for the major isomer are shown here, 
1
H-NMR (400 MHz, DMSO-
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d6) δ (ppm) 7.4 (m, 5H, Ar) 5.67 (s, 1H, Ar-CH), 4.24 (q, 
3
JH-H = 5 Hz, 1H, CO-CH), 
3.80 (m,1H, CH-CH2), 3.15 (m, 1H, CH-CH2) ;
 13
CNMR (101 MHz, DMSO-d6)  (ppm)   
172.95, 172.19 (C=O), 141.18, 139.91, 128.31, 127.25, 127.57,126.91, 71.73, 71.06, 654
0, 64.85, 38.39, 37.94; Electrospray ionization   (ESI) mass spectrometry (positive electro
n ionization)  m/z : 210.06017 ([M+H]
+
,100%), calculated for C10H11NO2S, m/z 
209.05105. 
(2S,4S) and (2R,4S) -2-phenyl-1,3-thiazinane-4-carboxylic acid (4.4) 
L-Hcy (1.88 mmol) and benzaldehyde (1.88 mmol) were added in 6 mL of DI water. 
Reaction mixture was stirred at RT for 72 hrs. The resultant precipitates were filtered 
washed with ice cold H2O and dried under vacuum. Compound 4.4 was obtained as a 
mixture of distereoisomers, colorless solid (273 mg, 65%); max (film)/cm
1 
1738  (C=O); 
M.P.177-178
°
C; 
1
H-NMR (400 MHz, DMSO-d6) δ (ppm) 7.55  (m, 5H, Ar), 5.27 (s, 1H, 
Ar-CH), 3.60 (dd, 
3
JH-H = 9, 3 Hz, 1H, CO-CH ), 3.28 (td, 
3
JH-H = 11, 3 Hz 
1H, S˗CH2,), 2.91 (dt, 
3
JH˗H = 10, 4 Hz, 1H, S˗CH2,), 2.10 (dq, 
3
JH˗H  =7.0, 3 Hz, 1H, CH˗
CH2), 1.51 (qd, 
3
JH˗H = 9, 4 Hz, 1H,CH˗CH2); 
13
CNMR, (101 MHz, DMSO d6) δ(ppm)   
173.5 (C=O), 140.8, 128.3 (overlapping), 127.8, 126.5, 64.1,  59.2, 28.9, 27.7; Electrospr
ay ionization (ESI) mass spectrometry (positive electron ionization) m/z :224.07707 ([M+
H]
+
,100%) calculated for C11H13NO2S, m/z 223.06670. 
(R)-thiazolidine-4-carboxylic acid (4.5) 
Synthesis of compound 4.5 has been reported in the literature, but for this work a 
modified and simpler procedure was used [126, 127]. Compound 4.5 was prepared by 
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following the procedure described for 4.1. Formaldehyde was used as the starting 
material instead of salicylaldehyde. Compound 4.5 was obtained as a mixture of distereoi
somers, colourless solid. (152 mg, 68.5%). max (film)/cm
1 
1617 (C=O); M.P.181˗182°C;  
1
H NMR (400 MHz, D2O) δ 4.52 (m, 1H CO CH and   2H, NH2CH2), 3.47 (m, 2H, 
CH˗CH2).
13
CNMR (101 MHz, D2O) δ (ppm) 171.9 (C =O), 63.9, 48.6, 32.9.Electrospray 
ionization (ESI) mass spectrometry (positive electron ionization) m/z : 134.0252  ([M+H]
+
,100%), calculated for C4H7NO2S, m/z 133.01975. 
 (S)-1,3-thiazinane-4-carboxylic acid (4.6)  
The synthesis of compound 4.6 has been reported in the literature [134]. Herein, a 
modified procedure to synthesize 4.6 has been used for the synthesis. L-Hcy (1.67 mmol) 
and formaldehyde (1.67 mmol) were added in 6 mL of DI water. The reaction mixture 
was stirred at RT for 48 h. The precipitates from the reaction mixture were filtered. 
Ethanol was added to the filtrate. The solution was kept at RT for 24 hrs. Transparent 
shiny crystal formation in the filtrate was observed. Crystals were filtered, washed with 
ice cold ethanol and dried under vacuum to yield 4.6 as colorless shiny crystals (135mg, 
55%)  
1
H NMR (400 MHz, D2O) δ 4.29 (m, 2H, NH-CH2-S), 3.68 (dd, 
3
JH-H = 10, 3 Hz,         
1H, CO-CH), 3.05 (m, 1H, S-CH2-CH2), 2.89 (m,1H, S-CH2˗CH2), 2.56 (m, 1H, CH-
CH2), 2.04 (qd, 
3
JH˗H = 10, 3 Hz, 1H, CHCH2); 
13
CNMR (101 MHZ, D2O)  173.3 
(C=O), 59.4, 45.1, 28.1, 26.0; Electrospray ionization (ESI) mass spectrometry (positive 
electron ionization) m/z : 148.04422 ([M+H]
+
,100%), calculated for C5H9NO2S, m/z 
147.03540. 
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CHAPTER 5  SYNTHESIS OF FLUORESCEIN TRI ALDEHDYE AND ITS 
APPLICATION IN THE DETECTION OF HCY 
5.1 Introduction  
In previous chapters, optimum conditions for the detection of Hcy using 3.1 (FMA) and 
3.3 (FDA) have been discussed. The mechanism behind this selectivity is based on 
differences in the basicity of Hcy and Cys derived heterocycles was also described. Based 
on this mechanism, the next goal was to design a more sensitive aldehyde-bearing 
fluorophore that can detect Hcy at its physiological levels in biological media. 
Compounds 3.1 and 3.3 didn’t exhibit an sufficiently low detection limit for an 
appreciable response from Hcy at concentrations below ~50 M in plasma (Figure 3-17). 
To achieve this goal fluorophore reactivity was increased by adding another reactive 
moiety and rendering the fluorophore ring more electrophilic. To implement this plan, it 
was decided to increase the number of aldehyde moieties on the fluorescein scaffold. As 
noticed before, the sensitivity of 3.3 was found to be twice of the sensitivity of 3.1. 
Therefore it seemed reasonable that to improve the sensitivity of fluorophore, the number 
of aldehyde moieties should be increased. Based on this concept, fluorophore, fluorescein 
trialdehyde was designed.  
5.2 Duff reaction and its application  
Several methods have been reported in the literature for the formylation of aromatic 
compounds [135, 136]. For example, the Riemer Tiemann reaction [137], Gatterman 
reaction, Gattermann-Koch reaction [138], Vilsmeier-Haack reaction [139], and Duff 
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reaction [140] are well known name reactions for the formylation of aromatic 
compounds. The Riemer Tiemann reaction was applied towards the synthesis of 3.1 and 
3.2. Both were obtained from the same reaction via a separation, unlike the long synthesis 
reported by Lippard et al. [141] where at first, 4,5-dimethyl fluorescein was synthesized 
from the reaction of 2-methyl resorcinol and phthalic anhydride, later hydroxyl groups of 
4,5-dimethyl fluorescein were protected with the help of benzoic anhydride. In the next 
step, Bromination of 4,5-dimethyl groups  was carried out over a period of more than 7 
days. Finally, bromo-methyl groups were converted to aldehyde groups by Swern 
oxidation to yield 3.2 with 36% yield [141].  
To synthesize fluorescein trialdehyde, a new synthetic strategy was used for the 
diformylation of the phenolic ring. Previously, ortho (to a hydroxyl) diformylation using 
The Duff reaction had been published [142] by Grylo et al. using a diverse range of 
phenols as shown in Scheme 5-1. The Duff reaction also has some advantages including 
relative simplicity and inexpensive, stable and relatively nontoxic reagents. 
 
                                                  Scheme 5-1. Duff formylation of phenol 
 
In 1934, An English scientist James Cooper Duff found that the reaction of 
hexamethylenetetramine with phenolic compound in acetic acid yielded a Schiff base, 
which upon hydrolysis in acidic medium, resulted in the ortho formyl product [143, 144]. 
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Since then The Duff reaction has been utilized for the direct diformylation of aromatic 
compounds in the synthesis of various drugs [145, 146], sensors [147, 148], and receptors 
[149] with some modifications. In the present work, the main focus was on the first 
application of The Duff reaction for the formylation of fluorescein to produce fluorescein 
trialdehyde. Attempts for the Synthesis of fluorescein tetra aldehyde were also made. 
5.3 Result and discussion  
Under The Duff reaction conditions, formylation of commercially available fluorescein 
was carried out by the reaction of fluorescein with hexamethylenetetramine in 
trifluoroacetic acid under an inert atmosphere followed by acid hydrolysis to afford 5.1 
i.e. fluorescein tri aldehyde (FTA) in a single step (Scheme 5.2) 
           
                                      Scheme 5-2. Synthesis of fluorescein tri aldehyde (5.1) 
 
Fluorescein tri aldehyde was obtained in 2% yield. The reason for the small yield was 
that, with the insertion of electron withdrawing aldehyde group in the fluorescein scaffold 
the nucleophilicity of the fluorophore decreases. Therefore the reactivity of the molecule 
towards electrophilic aromatic substitution for further formylation also reduces. As a 
result small yield of 5.1 was obtained and fluorescein tetra aldehyde could not be 
synthesized. Synthesis of 5.1, under The Duff reaction was attempted several times by 
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changing the number of equivalents of reactants and duration of the reaction. It was 
found that the ratio of fluorescein to HMTA (1:10 eqv) and duration of reaction i.e.72 hrs 
were the best parameters to synthesize 5.1.  
 Before the application of The Duff reaction, for the synthesis of fluorescein tri 
and tetra aldehyde, different reaction routes were also implemented. Formylation of tetra 
bromo fluorescein in THF with butyl lithium and DMF under various reaction conditions 
did not yield the desired product. formylation of tetra bromo fluorescein  by isopropyl 
bromide and DMF under different reaction conditions did not produce 5.1 either. Later, 
hydroxyl groups of tetra bromofluorescein were protected by benzoyl chloride . OH-
protected tetra bromofluorescein was subjected to formylation by isopropyl bromide and 
DMF. However this reaction did not succeed to give desired  product. Finally, phosphoryl 
chloride and DMF were used for the formylation of fluorescein under a number of 
different reaction conditions but none of them could produce formylated product. 
Study of response of Hcy and Cys towards 5.1 
To examine the sensitivity of this newly synthesized fluorophore 5.1, the reaction of Hcy 
and Cys with 5.1 was studied at pH 6.0 (Figure 5-1). As expected, in response to Hcy, a 
high fluorescence enhancement (~7 fold) was observed, whereas Cys didn’t show any 
appreciable change in the fluorescence. Later, the magnitude of the response towards Hcy 
with 3.1 and 3.3 (i.e. FMA and FDA) was also compared. The magnitude of fluorescence 
response of 5.1 towards Hcy was found to be more than  higher than that of 3.1 and 3.3 
(Figure 5-2).  
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Figure 5-1. Optical sensing behavior of 5.1 towards Hcy and Cys at pH 6.0.  
(a) Fluorescence spectral changes of 5.1 with Hcy and Cys after 2h. (b) Time dependent fluorescence 
spectral changes of 5.1 with Hcy and Cys. Solutions are composed of 4 µM of 5.1 with 1 mM of analyte in 
phosphate buffer (100 mM, pH 6.0) DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 595nm. 
 
 
(a) 
(b) 
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Figure 5-2. Comparison of magnitude of response of Hcy towards (a) 5.1, (b) 3.3, (c) 3.1. 
 Solutions are composed of 4 µM of probe with 1 mM of analyte in phosphate buffer (100 mM, pH 6.0) 
DMSO 99:1 at 20 ºC, λex = 495 nm and λem = 515nm 
 
After investigating the relative magnitude of the signal in the detection of Hcy 
with 5.1, its behavior towards Hcy and Cys was evaluated at physiologically relevant  
levels. On adding Hcy (15 M) in the presence of Cys (250 M) to a solution of 5.1, an 
(a) 
(b) 
(c) 
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enhancement in the fluorescence (~1.5 fold) was obtained. Cys at 250 M does not 
produce a change in the optical response of 5.1., as shown in the Figure 5-3. 
 
Figure 5-3. Optical sensing behavior of 5.1 towards Cys and Hcy at their biological concentrations at pH 
6.0.  
(a) Fluorescence spectra of 5.1 with Cys and Hcy after two hours. Solutions are composed of 30 µM of 3.3 
with 250 µM of Cys and 15 µM of Hcy in phosphate buffer (100 mM, pH 6.0):DMSO 99:1 at 20 
oC,  λex = 
494 nm and  λem = 525 nm. 
 
The response to Hcy was also investigated in the presence of various amino acids 
(Gly, Ala, Met, Gln, Glu, and Asp) along with Cys. Figure 5-4 shows that Hcy produces a 
distinct response in the presence of these related amino acid analytes. Other amino acids 
(a) 
(b) 
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and Cys produced a very small quenching in the fluorescence of 5.1. Whereas, Hcy 
produced almost 3 folds enhancement in the fluorescence. That shows the specificity of 
Hcy over other amino acids and Cys towards 5.1. Glutathione (GSH) produced no 
significant change in the fluorescence signal (Figure 5-4). Overall, these 
results demonstrated that 5.1 exhibited a distinct selectivity for Hcy. 
 
Figure 5-4. Optical sensing behavior of 5.1 towards Hcy and Cys  with and without  amino acids and GSH 
at pH 6.0 
fluorescence emission of 1 with Cys and Hcy  in presence and absence of amino acids and GSH after 2h. 
Solutions are composed of 4 µM of 5.1 with 50 µM of each analyte in phosphate buffer (100 mM, pH 
6.0):DMSO 99:1 at 20 
oC,  λex = 495 nm 
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Figure 5-5. (a) and (b)- Spectral response of 5.1 towards increasing levels of Hcy in phosphate buffer (100 
mM, pH 6.0 at 2h).  
Solutions are composed of 4 µM of 5.1 with 0-25 µM of Hcy in phosphate buffer (100 mM, pH 
6.0):DMSO 99:1at 20 
0C, λex = 495 nm and λex = 525 nm  
 
A concentration dependent experiment was also performed which indicated that 
the fluorescence response of 5.1 increased linearly with a limit of detection at 1.88 M as 
shown in Figure 5-5. LOD was calculated with the help of standard error, slope and 
intercept from the calibration curve graph. Standard error was obtained from the 
regression analysis in Microsoft Excel 2010.   
(a) 
(b) 
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Further, at the physiological levels of thiols, the response of 5.1 towards Hcy and 
Cys was investigated in deproteinized plasma. Results show that probe 5.1 was also 
capable of detecting Hcy in biological media. To measure the known amount of Hcy, 
deproteinized plasma was spiked with the known concentration of Hcy.  In deproteinized 
plasma, addition of Hcy to a solution of 5.1 enhances the fluorescence. In contrast, no 
significant change in the emission intensity was observed upon addition of Cys. (Figure 
5-6) With an increase in the concentration of Hcy, increase in the fluorescence emission 
was also observed in deproteinized plasma, as shown in Figure 5-7. 
 
Figure 5-6.  Optical sensing behavior of 5.1 towards Cys and Hcy in deproteinized plasma at pH 6.0.after 
2h. 
Solutions are composed of 20 µM of 5.1 with 250 µM of Cys and 15 µM of Hcy in phosphate buffer (100 
mM, pH 6.0):DMSO 99:1 at 20 
oC, λex = 495 nm 
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Figure 5-7. Optical sensing behavior of 5.1 towards Cys and Hcy in deproteinized plasma at pH 6.0.after 
2h.  
Solutions are composed of 20 µM of 5.1 with 5,10, 15, 20 and 25 µM of Hcy in phosphate buffer (100 mM, 
pH 6.0):DMSO 99:1 at 20 
oC, λex = 495 nm 
 
As previously explained fluorescence enhancement of 5.1 by the addition of Hcy 
was due to the formation of thiazinane-4-carboxylic acid, and subsequent protonation of 
the amine, producing an ammnonium species at pH 6.0 to inhibit PET. To confirm the 
PET inhibition based response of Hcy to 5.1, the reaction of Hcy and Cys was studied at 
lower pH (5.0), intermediate pH (6.0) and higher pH (9.5). In Figure 5-8, it is evident that 
at lower pH (5.0), the thiazinane and thiazolidines are in the ammonium form, since 
fluorescent enhancement occurs. Conversely, at pH 6.0, the ammonium of the thiazinane 
is the predominant species in contrast to Cys-derived thiazolidine, wherein the 
ammonium and amine species exist in nearly equal amounts. At higher pH (9.5), the 
amine of both heterocycles have their lone pairs available for PET quenching.  
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Figure 5-8. Optical sensing behavior of 5.1 towards Cys and Hcy in buffer at different pH, after 2h.  
Fluorescence spectra of 5.1 with Cys  and Hcy (a) at pH 5.5 in phosphate buffer, (b) at pH 6.0 in phosphate 
buffer, (c) at pH 9.5 in carbonate buffer  .Solutions are composed of 4 µM of 5.1 with 1 mM of analyte in 
100 mM buffer solution: DMSO( 99:1) at 20 
oC, λex = 495 nm 
 
Apart from being selective, the enhanced sensitivity of the probe 5.1 is due to the 
presence of three electron withdrawing aldehyde groups that makes the fluorophore 
scaffold more electrophilic and reactive. Previously, Huang et al. calculated the surface 
charges based on density functional theory (DFT) for an aldehyde-bearing iridium (III) 
complex. They found that charges on the N and S atoms of thiazolidine are more negative 
than the charges on the N and S atoms of thiazinane. According to them, higher negative 
charges on the thiazolidine can result in an intramolecular electron-transfer process from 
the thiazolidine group to the excited complex, causing a weak photoluminescence of the 
probe-Cys complex [109].  
In the current case, as shown in Table 5.1, the Mulliken charges on the N and S 
(a) (b) 
(c) 
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atoms for Cys-derived thiazolidine are more negative ( N,-0.650223 and S,-0.384138) 
when compared to the N and S atoms of Hcy-derived thiazinane (N,-0.399059 and S,-
0.078137). This is in agreement with the results reported by Huang et al. for the 
intramolecular electron transfer process from the thiazolidine group resulting in 
fluorescence quenching or weak enhancement [109].  
Table 5.1 Comparison Mulliken charges on the ‘N’ and ‘S’ of Cys and Hcy derived heterocycles formed 
upon reaction with 5.1 
  Mulliken charges Mulliken charges 
5.1+Hcy ‘N’ -0.202843,  
-0.194407,  
-0.209806 
‘S’ -0.020108, 
 - 0.043911,  
-0.059903 
5.1+Cys ‘N’ -0.542689, 
 -0.544021, 
 -0.529787 
‘S’ -0.136779,  
-0.218184,         
 -0.358607 
 
 
Further, the selective signaling for Hcy in terms of ionic charges can also be 
explained. From the Mulliken charge calculations, it was found that the phenolate anion 
and the ether oxygen of the thiazinane (Hcy)-dye adduct bear higher negative charges (-
0.729, - 0.686 and -0.326, respectively) than of the Cys-derived thiazolidine (-0.508, -
0.621 and -0.280, respectively) and 5.1 (-0.659, -0.576 and -0.261, respectively, Table 
5.2 and Figure 5-9). The development of enhanced negative charge density on the 
fluorophore phenolate oxygen upon formation of the Hcy-derived thiazinane results in an 
increase in fluorescence emission.  
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Figure 5-9. Predominant species of compounds 5.1, 5.1a and 5.1b at pH 6.0. Calculated Mulliken charges 
are shown for the oxygen atoms in the fused ring system. 
 
Table 5.2 Comparison Mulliken charges on the phenolate ‘O’ and ether ‘O’ of 5.1 and Cys and Hcy 
derived heterocycles formed upon reaction with 5.1 
                                                     Mulliken charges 
5.1 Phenolate  oxygen,  
ether oxygen  
 -0.65882, -0.575738,  
-0.261133 
 
5.1+Hcy Phenolate  oxygen,  
ether oxygen  
  -0.729433, -0.686371,  
-0.325709        
 
5.1+Cys Phenolate  oxygen,  
ether oxygen  
-0.508089, -0.620732, 
 -0.280251      
 
 
5.5 Conclusion  
In conclusion, a highly selective fluorescein trialdehyde for the detection of Hcy at its 
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physiological level in biological media has been developed. At pH 6.0, protonation of the 
amine of the Hcy-derived thiazinane takes place due to its higher basicity compared to 
the amine of the Cys-derived thiazolidne. The protonation results in inhibition of PET 
quenching and selective signaling for Hcy. The presence of three electron-withdrawing 
aldehyde groups makes the fluorophore highly reactive and enhances the Hcy detection 
limit. Mulliken charge calculations reveal that the Hcy-derived thiazinane renders the 
fluorophore phenoxide oxygen more electron-rich leading to fluorescence enhancement 
as compared to the Cys-derived thiazolidine. 
5.4 Experimental section  
5.4.1 Materials  
All chemicals were purchased from Sigma Aldrich and used as received. Ultra-pure water 
(18.2 MΩ·cm at 25 °C) obtained from a Milli-Q direct water purification system was 
utilized to prepare all aqueous solutions. All spectroscopic measurements were conducted 
in DMSO:buffer (1:99) solutions.  
5.4.2 Methods  
1
H NMR and 
13
C-NMR were recorded on a ARX-400 Advance Bruker spectrometer 
performing at 400.13 MHz (
1
H) and 100.61 MHz (
13
C).  All chemical shifts chemical 
shifts (δ) were reported in ppm using DSS (sodium 2, 2-dimetyl-2-silapentane-5-
sulfonate) as an internal standard (=0.000) for 1H NMR studies. CF3COOD was used as 
a NMR solvent to record 
1
H NMR spectra. 
13
C NMR of 5.1 was obtained in CDCl3 and 
CF3COOD (1:8) solvent system . ESI-HRMS (high resolution mass spectrometry) spectra 
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was recorded at the PSU Bioanalytical Mass Spectrometry Facility on a ThermoElectron 
LTQ-Orbitrap high resolution mass spectrometer. IR spectrum was obtained by Fourier 
transform infrared (FT-IR) spectroscopy operated on a Thermo Scientific Nicolet iS10 
spectrophotometer equipped with a single-bounce diamond ATR attachment. 
5.4.3 Spectrophotometric measurement 
UV-visible spectra were recorded on a Cary 50 UV-Vis spectrophotometer (Agilent 
Technologies). Fluorescence spectra were recorded on a Cary Eclipse fluorescence 
spectrophotometer (Agilent Technologies) with slit widths set at 5 nm for both excitation 
and emission, respectively. Fluorescence spectra were corrected for the wavelength 
dependent response of the R928 photomultiplier tube with the help of a manufacturer 
generated correction file. All spectrophotometric measurements were conducted at room 
temperature. 
5.4.3 Deproteinization of plasma  
Deproteinization of plasma was carried out by following the procedure described in the 
section 3.6.4.  
5.4.4 Mulliken charges calculation  
Molecular models of compounds 5.1, 5.1a and 5.1b were built and subjected to geometry 
optimization and Mulliken population analysis using the PM7 hamiltonian in 
MOPAC2012 [150, 151]. 
5.4.5 Synthesis of 5.1 
Fluorescein (1 eqv, 7.52 mmol) was dissolved in a minimum amount of trifluoroacetic 
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acid. Hexamethylene tetraamine (10 eqv, 75.23 mmol) was added slowly to the 
fluorescein solution under Ar atmosphere at RT. Reaction mixture was stirred at 70
0
C for 
72 hrs under Ar and then at 100
°
C for extra 4 hrs. Afterward, 30 mL of 1N HCl was 
added to the reaction mixture and stirred at 100 
°
C for additional 1hr. This resulted in the 
formation of orange precipitates. The reaction mixture was left at RT for 15 hrs. Orange 
precipitates were filtered, washed with water and dried under vacuum. Later, probe 5.1 
was separated by column chromatography (CHCl3: MeOH, 98:2 and DCM: EtOAc 97:3). 
Product was obtained as colorless solid with 2 % yield (62 mg). Rf = 0.3 (3% Ethyl 
acetate in dichloromethane, SiO2); M.P. > 200 
°
C; 
1
H NMR (400 MHz, CDCl3) δ 10.74 
(s, 1H, CHO), 10.62 (s, 1H, CHO), 9.93 (s, 1H, CHO), 8.17 (m,  1H), 7.84 (s, 1H), 7.74 
(m, 2H), 7.25  (m, 2H), 6.94 (m, 1H); 
13
C NMR (101 MHz, CDCl3) δ 189.7 (CHO), 
187.6(overlapping, CHO), 166.3 (COOH), 153.7, 152.8 , 137.9 , 133.6 , 131.9, 127.8, 
125.1, 122.4, 122, 120.8 , 117.9 , 115.5, 111.9, 110.8, 109.6 -108 (overlapping), 104.4; 
max (film)/cm
1   
1738 (C=O);. Electrospray ionization (ESI) mass spectrometry (negative 
electron ionization) m/z: 415.04610 (100% (M-H]
+
, calculated for C23H12O8 m/z: 
416.05322 (100.0%). 
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APPENDIX A : CHARACTERIZATION OF COMPOUNDS 4.1 AND 4.2  
 
                                             
 Figure A-1.
1
HNMR of 4.1 and 4.2 
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Figure A-2 
13
CNMR of 4.1 and 4.2 
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Figure A-3. Mass spectrum of 4.1 and 4.2 
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APPENDIX B : CHARACTERIZATION OF COMPOUND 4.3 AND 4.4  
        
   Figure B-1. 
1
HNMR of 4.3 and 4.4  
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Figure B-2. 
13
CNMR of 4.3 and 4.4 
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Figure B-3. Mass spectrum of 4.3.and 4.4 
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APPENDIX C : CHARACTERIZATION OF COMPOUND 4.5 AND 4.6 
 
Figure C-1.
 1
HNMR of 4.5 and 4.5 
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Figure C-2. 
13
CNMR of 4.5 and 4.6  
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Figure C-3. Mass spectrum of 4.5 and 4.6 
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APPENDIX D : CHARACTERIZATION OF COMPOUNDS 5.1 
 
Figure D-1.
 1
HNMR of 5.1 
                      
Figure D-2. 
13
NMR of 5.1 
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Figure D-3. Mass spectrum of 5.1  
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APPENDIX E : COLORIMETRIC RESPONSE OF THIOLS TOWARDS 5.1 
 
Figure E-1. Optical sensing behavior of 5.1 towards Hcy at pH 6.0, Time course absorbance spectral 
changes of 5.1 with Hcy, Solutions are composed of 4 µM of 5.1 with 50 M of analyte in phosphate buffer 
(100 mM, pH 6.0):DMSO 99:1 at 20 ºC 
 
Figure E-2. Optical sensing behavior of 5.1 towards Cys at pH 6.0, Time course absorbance spectral 
changes of 5.1 with Cys, Solutions are composed of 4 µM of 5.1 with 50 M of analyte in phosphate buffer 
(100 mM, pH 6.0):DMSO 99:1 at 20 ºC 
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APPENDIX F : ENERY MINIMIZED SIMULATED 3D STRUCTURE OF 5.1, 
5.1A AND 5.1B' 
 
Figure F-1. Energy minimized 3D structure of 5.1  
 
Figure F-2.  Energy minimized 3D structure of 5.1b (Hcy-5.1) 
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Figure F-3. Energy minimized 3D structure of 5.1a (Cys-5.1). 
 
 
 
